

Available online at www.sciencedirect.com



Tetrahedron

Tetrahedron 62 (2006) 7674-7686

Synthesis of chromanes by sequential '[3+3]-cyclization/ Williamson' reactions of 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes

Van Thi Hong Nguyen,^a Bettina Appel^a and Peter Langer^{b,c,*}


^aInstitut für Biochemie, Universität Greifswald, Soldmannstr. 16, 17487 Greifswald, Germany ^bInstitut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany ^cLeibniz-Institut für Katalyse e. V. an der Universität Rostock, Albert-Einstein-Str. 29a, 18059 Rostock, Germany

> Received 17 April 2006; revised 24 May 2006; accepted 29 May 2006 Available online 16 June 2006

Abstract—Functionalized chromanes were prepared by sequential '[3+3]-cyclization/Williamson' reactions of 1,3-bis(trimethylsilyloxy)-7chlorohepta-1,3-dienes with 1,1,3,3-tetramethoxypropane, 3-silyloxyalk-2-en-1-ones, and 1,1-diacetylcyclopropane. The first step of the sequence involves [3+3] cyclizations of the starting materials to give 2-(3-chloropropyl)phenols. The subsequent cyclization proceeds by intramolecular nucleophilic substitution. 6-(2-Hydroxybenzoyl)chromanes were prepared based on sequential '[3+3]-cyclization/Williamson' reactions of 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes with 3-formylchromones. © 2006 Elsevier Ltd. All rights reserved.

1. Introduction

3,4-Dihydro-2*H*-chromenes (chromanes) represent pharmacologically relevant heterocycles, which occur in a variety of natural products (Scheme 1).^{1,2} For example, bavachromanol has been isolated from leaves of *Maclura tinctoria* L. (Venezuela).^{2a} The chromanol moiety of vitamin E



Scheme 1. Chromane natural products.

0040–4020/\$ - see front matter 0 2006 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2006.05.076

(α -tocopherol) exhibits anti-androgen properties. Many synthetic approaches to 3,4-dihydro-2*H*-chromenes are based on intramolecular Friedel–Crafts alkylations.² Finn et al. have prepared chromanes from salicylic aldehydes and vinylboronic acids in the presence of catalytic amounts of dibenzylamine.³ Jones et al. reported the synthesis of chromanes by Diels–Alder reactions of *o*-quinone methides, which were generated from salicylic aldehydes and alcohols.⁴

Chan and co-workers reported an efficient one-pot synthesis of salicylates based on [3+3] cyclizations of 1,3-bis-silyl enol ethers⁵ with 3-silyloxyalk-2-en-1-ones or 1,1,3,3-tetramethoxypropane.⁶ Recently, we have reported⁷ an extension of this method by the first use of 1,3-bis-(trimethylsilyloxy)-7-chlorohepta-1,3-dienes (chloro-substituted 1,3-bis-silyl enol ethers)⁸ in [3+3] cyclizations. The combination of these [3+3] cyclizations with subsequent intramolecular Williamson reactions allows for the synthesis of functionalized chromanes. Herein, we report full details of these studies. With regard to our preliminary communication in this field,⁷ we herein report, for the first time, the synthesis of 6-(2-hydroxybenzoyl)-3,4-dihydro-2H-chromenes based on sequential '[3+3]-cyclization/Williamson' reactions of 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes with 3-formylchromones. The general strategy reported herein allows for a convenient synthesis of a variety functionalized chromanes. Notably, the substitution patterns of these products are not readily available by other methods.


Keywords: Benzopyrans; Cyclizations; Ethers; Lewis acids; Silyl enol ethers.

^{*} Corresponding author. Tel.: +49 381 4986410; fax: +49 381 4986412; e-mail: peter.langer@uni-rostock.de

2. Results and discussion

2.1. [3+3] Cyclization of 1,1,3,3-tetramethoxypropane


The key substrates of this study—1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes **1a,b**—were prepared in three steps from ethyl acetoacetate as previously reported.^{7,9} The TiCl₄mediated [3+3] cyclization of **1a** with 1,1,3,3-tetramethoxypropane (**2**) afforded the 2-(3-chloropropyl)phenol **3a**. The formation of **3a** proceeds by attack of carbon atom C-4 of **1a** onto **2**, cyclization via carbon C-2, and finally aromatization. Notably, the chloride functionality remained unattacked during the reaction. Treatment of a THF solution of **3a** with sodium hydride (NaH), in the presence of tetrabutylammonium iodide (TBAI), afforded chromane **4a** (Scheme 2).



Scheme 2. Synthesis of chromane 4a. Reagents and conditions: (i) TiCl₄, CH₂Cl₂, $-78 \rightarrow 20$ °C; (ii) NaH, TBAI, THF, 20 °C.


2.2. [3+3] Cyclizations of 3-silyloxyalk-2-en-1-ones

The [3+3] cyclization of 1,3-bis-silyl enol ether **6a** with 3-silyloxyalk-2-en-1-one **5a** has been reported to give salicylate **7**.⁶ The cyclization proceeds by TiCl₄-mediated conjugate addition of the terminal carbon atom of the bis-silyl enol ether onto **5a**, cyclization, extrusion of siloxane, and aromatization (Scheme 3).



Scheme 3. Synthesis of salicylate 7 by Chan et al. Reagents and conditions: (i) TiCl₄, CH₂Cl₂, $-78 \rightarrow 20$ °C.

The [3+3] cyclization of 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes **1a,b** with 3-silyloxyalk-2-en-1-ones **5a–d** afforded the 2-(3-chloropropyl)phenols **3b–h**. The latter were transformed (by NaH and TBAI) into chromanes **4b–h** (Scheme 4, Table 1). The formation of **3b–h** can be explained, following the mechanism proposed by Chan,⁶ by initial attack of carbon atom C-4 of **1a,b** onto the carbon atom attached to the silyloxy group of **5a–d**, cyclization by attack of carbon C-2 onto the carbonyl group and subsequent aromatization.




Scheme 4. Synthesis of chromanes 4b–h. Reagents and conditions: (i) TiCl₄, CH₂Cl₂, $-78 \rightarrow 20$ °C; (ii) NaH, TBAI, THF, 20 °C.

Table 1. Synthesis of chromanes 4b-h

5	3,4	R^1	R^2	R^3	% (3) ^a	% (4) ^å
a	b	Me	Me	Н	52	90
b	с	Me	Н	Н	46	70
с	d	Me	Et	Н	43	82
d	e	Et	Н	Н	42	65
a	f	Me	Me	Me	44	94
b	g	Me	Н	Me	46	80
c	ĥ	Et	Н	Me	53	97


^a Yields of isolated products.

The [3+3] cyclization of 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-diene **1a** with 3-silyloxyalk-2-en-1-one **5e**, prepared from 2-(hydroxymethylidene)cyclohexan-1-one, furnished tetrahydronaphthalene **3i** (Scheme 5). In contrast to **3b–h**, the formation of regioisomers is theoretically possible in case of **3i**. The regioselective formation of **3i** can be explained by the same mechanism as described for **3b–h**, i.e. by initial attack of carbon atom C-4 of **1a** onto the carbon attached to the silyloxy group of **5e**. Treatment of **3i** with NaH/TBAI afforded the tricyclic benzopyran **4i**. The structure of **4i** was established by H,H-COSY, C,H-COSY, HMBC, and NOESY experiments.



Scheme 5. Synthesis of chromane 4i. Reagents and conditions: (i) $TiCl_4$, CH_2Cl_2 , $-78 \rightarrow 20$ °C; (ii) NaH, TBAI, THF, 20 °C.

The [3+3] cyclization of **1a** with 3-silyloxyalk-2-en-1-one **5f**, available by silylation of 2-acetylcyclohexanone, regioselectively afforded **3j**, which was transformed into the tricyclic chromane **4j** (Scheme 6, Table 2). The formation of **3j** can be explained by TiCl₄-mediated isomerization of **5f** into *iso*-**5f** and subsequent attack of carbon C-4 of **1a** onto the carbon attached to the silyloxy group of *iso*-**5e**. The structure of **4j** was established by H,H-COSY, C,H-COSY, HMBC, and NOESY experiments. The cyclization of **1a** with 3-silyloxyalk-2-en-1-one **5g**, prepared from 2-acetyl-tetralone, regioselectively afforded **3k**, which was transformed into the tetracyclic chromane **4k**. The formation of **3k** presumably follows the mechanism as discussed for **3j**. The structure of **4k** was established by H,H-COSY, C,H-COSY, HMBC, and NOESY experiments. Notably, the structures of **3j,k** and **4j,k** have to be revised with respect to our preliminary communication.



Scheme 6. Synthesis of chromanes 4j,k. Reagents and conditions: (i) TiCl₄, CH₂Cl₂, $-78 \rightarrow 20$ °C; (ii) NaH, TBAI, THF, 20 °C.

 Table 2. Products and yields

3,4	R^1	R^2	% (3) ^a	% (4) ^a		
j k	-(CH -(CH ₂)	$(I_2)_4 - I_2 C_6 H_4 - I_2 $	34 27	87 88		


^a Isolated yields.

2.3. [3+3] Cyclizations of 1,1-diacetylcyclopropane

We have recently reported⁹ the synthesis of 2-(3-chloropropyl)-4-(2-chloroethyl)phenol **3**l by TiCl₄-mediated cyclization of **1a** with 1,1-diacetylcyclopropane (**6**) (Scheme 7). The formation of **3**l can be explained by initial [3+3] cyclization to give a spirocyclopropane, which is cleaved by attack of TiCl₄ (homo-Michael reaction).¹⁰ Likewise, the TiBr₄-mediated cyclization of **1a** with **6** furnished 2-(3-chloropropyl)-4-(2-bromoethyl)phenol **3m**. Treatment of **3**l,**m** with NaH/ TBAI afforded the novel functionalized chromanes **4**l,**m**.


2.4. [3+3] Cyclizations of 3-formylchromones

We have recently reported the reaction of 1,3-bis-silyl enol ethers with 3-formylchromones to give functionalized benzophenones.¹¹ The formation of the products can be explained by a domino 'Michael/Retro-Michael/Aldol' reaction following the mechanism as given in Scheme 8. The reaction can be formally regarded as a [3+3] cyclization of an activated enal and resemble the [3+3] cyclizations of 1,3-bis-silyl enol ethers with 3-silyloxyalk-2-en-1-ones discussed above. Herein, we




Scheme 7. Synthesis of chromanes 41,m. Reagents and conditions: (i) TiX₄ (X=Cl, Br, 2 equiv), CH₂Cl₂, $-78 \rightarrow 20$ °C; (ii) NaH, TBAI, THF, 20 °C.

report the reaction of formylchromones with 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes, which allow for an efficient synthesis of 6-(2-hydroxybenzoyl)-3,4-chromanes.



Scheme 8. Mechanism of the cyclization of 1,3-bis-silyl enol ethers with 3-formylchromones (Ref. 11). Reagents and conditions: (i) Me₃SiOTf (0.3 equiv), 20 °C, 10 min; (ii) (1) **2a** (1.3 equiv), CH_2Cl_2 , $0 \rightarrow 20$ °C, 12 h; (2) HCl (10%).

The TMSOTf catalyzed reaction of 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes **1a,b** with 3-formylchromones **8a–e** afforded the 4-(2-hydroxybenzoyl)salicylates **10a–h** containing a remote chloride group (Scheme 9, Table 3). The mechanism of these reactions can be explained analogously to the formation of **9** (Scheme 8). Treatment of **10a–h** with NaH/TBAI afforded the 6-(2-hydroxybenzoyl)-3,4-dihydro-2*H*-chromenes **11a,b,e–h** by intramolecular Williamson reaction. These products were isolated in the form of their carboxylic acids (except for 11a); the hydrolysis of the ester group presumably occurred during the aqueous work-up using hydrochloric acid (10%). Notably, the employment of the latter proved to be mandatory for a successful isolation of any type of product of this reaction.



Scheme 9. Synthesis of 11a–h. Reagents and conditions: (i) (1) Me_3SiOTf (0.3 equiv), 0 °C, 10 min; (2) 1a,b (1.3 equiv), CH_2Cl_2 , 20 °C, 12 h; (3) HCl (10%); (ii) NaH (1.5 equiv), TBAI (2.0 equiv), THF, 20 °C, 20 h; for 11b,e–h: HCl (10%).

Table 3. Products and yields


8	1	10/11	R^1	R^2	R^3	R^4	% (10)	% (11) ^a
a	a	а	Н	Н	Н	Et	41	68
b	a	b	Me	Н	Н	Н	54	94
c	a	с	Et	Н	Н	Н	48	b b
d	a	d	Cl	Н	Н	Н	51	b
e	a	e	Cl	Me	Н	Н	47	70
a	b	f	Н	Н	Me	Н	43	71
b	b	g	Me	Н	Me	Н	41	86
d	b	ĥ	Cl	Н	Me	Н	38	73

^a Isolated yields.

^b Experiment not carried out.

2.5. [4+2] Cyclization of 2-bromonaphthalene-1,4-dione

Some years ago, Brassard et al. reported the [4+2] cycloaddition of 1,3-bis-silyl enol ethers with bromoquinones to give anthraquinones.¹² The reaction of **1a** with 2-bromonaphthalene-1,4-dione (**12**) afforded the functionalized anthraquinone **13**. Surprisingly, the product contained a bromide group located at the benzene moiety formed during the reaction. Treatment of **13** with NaH/TBAI afforded chromane **14** (Scheme 10). The formation of **13** can be explained by a radical mechanism.



Scheme 10. Synthesis of 14. Reagents and conditions: (i) (1) THF, 1 h, $-78 \degree C$, (2) 14 h, $-78 \rightarrow 20 \degree C$, (3) HCl (10%); (ii) NaH, TBAI, THF, 20 $\degree C$.

3. Conclusions

We have reported the synthesis of functionalized chromanes by double-annulation reactions of 1,3-bis(trimethylsilyloxy)-7-chlorohepta-1,3-dienes with 1,1,3,3-tetramethoxypropane, 3-silyloxyalk-2-en-1-ones, and 1,1-diacetylcyclopropane. The products were formed by [3+3] cyclization of the starting materials to give 2-(3-chloropropyl)phenols and subsequent cyclization by intramolecular nucleophilic substitution. 6-(2-Hydroxybenzoyl)chromanes were prepared based on double-annulation reactions of 3-formylchromones; an anthraquinone derived chromane was prepared from 2-bromonaphthoquinone. The general strategy reported herein allows for a convenient synthesis of a variety of functionalized chromanes. Notably, the substitution patterns of these products are not readily available by other methods.

4. Experimental

4.1. General

All solvents were dried by standard methods and all reactions were carried out under an inert atmosphere. For ¹H and ¹³C NMR spectra, the deuterated solvents indicated were used. Mass spectrometric data (MS) were obtained by electron ionization (EI, 70 eV), chemical ionization (CI, H₂O), or electrospray ionization (ESI). For preparative scale chromatography, silica gel (60–200 mesh) was used. Melting points are uncorrected.

4.2. General procedure for the synthesis of salicylates **3a-k**

To a CH₂Cl₂ solution of **1a**,**b** and **2** or **5a**–**g** was dropwise added TiCl₄ at -78 °C under argon atmosphere. The solution was stirred at -78 °C for 30 min and was subsequently warmed to 20 °C within 18 h. To the solution was added a saturated aqueous solution of NaHCO₃. The organic and the aqueous layer were separated and the latter was extracted with ether. The combined organic layers were dried (Na₂SO₄), filtered, and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, *n*-hexane/EtOAc).

4.2.1. Ethyl 3-(3-chloropropyl)-2-hydroxybenzoate (3a). Starting with 1a (1.75 g, 5.0 mmol), 2 (0.8 g, 5.0 mmol), and TiCl₄ (0.94 g, 5.0 mmol) in CH₂Cl₂ (15 mL), 3a was isolated after chromatography (silica gel, n-hexane/ EtOAc = 30:1) as a colorless oil (0.5 g, 42%). ¹H NMR (CDCl₃, 300 MHz): δ=1.41 (t, J=7.1 Hz, 3H, CH₃), 2.11 (quint, J=6.5 Hz, 2H, CH₂), 2.82 (t, J=7.1 Hz, 2H, CH₂), 3.54 (t, J=6.6 Hz, 2H, CH₂-Cl), 4.41 (q, J=7.1 Hz, 2H, OCH₂), 6.18 (m, 1H, CH of Ar), 7.32–7.35 (m, 1H, CH of Ar), 7.75 (d, 1H, CH of Ar), 11.13 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =14.2 (CH₃), 21.2, 31.9, 44.6, 61.4 (CH₂), 112.3, 118.6, 128.0, 128.9 (C), 135.9 (CH), 159.9, 170.6 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 3140$ (m), 2986 (m), 1671 (s), 1615 (s), 1449 (s), 1401 (s), 1374 (s), 1297 (s), 1249 (s), 1178 (s), 1152 (s), 1087 (m), 1026 (m), 761 (s), 725 (m). UV–vis (CH₃CN, nm): λ_{max} (log ε)=212 (4.42), 242 (3.92), 310 (3.55) nm. MS (EI, 70 eV): m/z (%)=244 $(M^{+}[^{37}Cl], 11), 242 (M^{+}[^{35}Cl], 34), 196 (19), 161 (100),$

134 (44), 105 (21), 77 (24), 51 (9), 27 (10). HRMS (ESI): calcd for $C_{12}H_{16}ClO_3$ ([M+1]⁺): 245.07584 [³⁷Cl], 243.07879 [³⁵Cl]; found: 245.07565 [³⁷Cl], 243.0787 [³⁵Cl]. Anal. Calcd for $C_{12}H_{15}ClO_3$ (242.699): C, 59.39; H, 6.23. Found: C, 60.88; H, 6.36.

4.2.2. Ethyl 3-(3-chloropropyl)-2-hydroxy-4,5,6-trimethylbenzoate (3b). The synthesis of **3b** has been previously reported.⁹ Starting with **1a** (1.23 g, 3.5 mmol), **5a** (0.61 g, 3.5 mmol), and TiCl₄ (0.66 g, 3.5 mmol) in CH₂Cl₂ (10 mL), **3b** was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (0.516 g, 52%).

4.2.3. Ethyl 3-(3-chloropropyl)-2-hydroxy-4,6-dimethylbenzoate (3c). Starting with 1a (2.90 g, 8.2 mmol), 5b (1.42 g, 8.2 mmol), and TiCl₄ (1.55 g, 8.2 mmol) in CH₂Cl₂ (15 mL), 3c was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (1.02 g, 46%). ¹H NMR (CDCl₃, 300 MHz): δ =1.42 (t, J=7.1 Hz, 3H, CH₃), 2.00 (quint, J=6.6 Hz, 2H, CH₂), 2.25 (s, 3H, CH₃), 2.49 (s, 3H, CH₃), 2.78 (t, J=7.7 Hz, 2H, CH₂), 3.61 (t, J=6.7 Hz, 2H, CH₂-Cl), 4.42 (q, J=7.1 Hz, 2H, OCH₂), 6.54 (s, 1H, CH), 11.76 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.2, 19.8 (CH₃), 23.6, 23.9, 31.8, 45.3, 61.4 (CH₂), 109.7 (C), 124.8 (CH), 125.2, 138.4, 143.1, 161.1, 172.2 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 2977$ (s), 2937 (s), 1938 (w), 1653 (s), 1563 (m), 1447 (s), 1396 (s), 1376 (s), 1349 (s), 1311 (s), 1273 (s), 1232 (s), 1175 (s), 1037 (s), 848 (s), 811 (s). UV-vis (CH₃CN, nm): λ_{max} (log ε)= 216 (4.45), 253 (4.00), 316 (3.60) nm. MS (EI, 70 eV): m/z (%)=272 (M⁺[³⁷Cl], 6), 270 (M⁺[³⁵Cl], 21), 224 (20), 189 (100), 162 (25), 133 (7), 105 (5), 91 (10), 27 (5.3). HRMS (ESI): calcd for C₁₄H₂₀ClO₃ ([M+1]⁺): 273.10714 [³⁷Cl], 271.11009 [³⁵Cl]; found: 273.10647 [³⁷Cl], 271.10950 [³⁵Cl]. Anal. Calcd for C₁₄H₁₉ClO₃ (270.752): C, 62.11; H, 7.10. Found: C, 61.20; H, 7.80.

4.2.4. Ethyl 3-(3-chloropropyl)-5-ethyl-2-hydroxy-4,6-dimethylbenzoate (3d). Starting with 1a (1.75 g, 5.0 mmol), 5c (1.42 g, 5.0 mmol), and TiCl₄ (0.94 g, 5.0 mmol) in CH₂Cl₂ (15 mL), **3d** was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (0.630 g, 43%). ¹H NMR (CDCl₃, 300 MHz): $\delta_{\rm C}$ =1.10 (t, J=7.2 Hz, 3H, CH₃), 1.39 (t, J=7.1 Hz, 3H, CH₃), 1.99 (quint, J=6.7 Hz, 2H, CH₂), 2.30 (s, 3H, CH₃), 2.46 (s, 3H, CH₃), 2.65 (q, J=7.5 Hz, 2H, CH₂), 2.85 (m, J=6.0 Hz, 2H, CH₂), 3.61 (t, J=6.7 Hz, 2H, CH₂-Cl), 4.43 (q, J=7.1 Hz, 2H, OCH₂), 10.83 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): δ=13.7, 14.2, 15.9, 18.3 (CH₃), 22.8, 24.1, 30.1, 45.3, 61.4 (CH₂), 111.5, 125.3, 133.1, 135.1, 141.3, 157.3, 172.1 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 2967$ (s), 2874 (m), 1726 (m), 1651 (s), 1599 (s), 1448 (s), 1701 (s), 1375 (s), 1322 (s), 1269 (s), 1195 (s), 1090 (s), 1037 (s), 806 (s), 768 (m). UV–vis (CH₃CN, nm): λ_{max} (log ε)=218 (4.42), 256 (3.95), 320 (3.58) nm. MS (EI, 70 eV): m/z $(\%)=300 (M^{+}[^{37}Cl], 3), 298 (M^{+}[^{35}Cl], 14), 252 (20), 217$ (100), 189 (16), 176 (40), 161 (30), 91 (8), 28 (44). Anal. Calcd for C₁₆H₂₃ClO₃ (298.805): C, 64.31; H, 7.76. Found: C, 64.35; H, 8.10.

4.2.5. Ethyl 3-(3-chloropropyl)-4,6-diethyl-2-hydroxybenzoate (3e). Starting with **1a** (1.75 g, 5.0 mmol), **5d** (1.00 g, 5.0 mmol), and TiCl₄ (0.94 g, 5.0 mmol) in CH_2Cl_2

(15 mL), 3e was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (0.62 g, 41%). ¹H NMR (CDCl₃, 300 MHz): δ =1.21 (t, J=7.5 Hz, 6H, $2 \times CH_3$), 1.42 (t, J=7.2 Hz, 3H, CH₃), 2.02 (quint, J=7.2 Hz, 2H, CH₂), 2.62 (q, J=7.6 Hz, 2H, CH₂), 2.79 (m, J=6.0 Hz, 2H, CH₂), 2.91 (q, J=7.5 Hz, 2H, CH₂), 3.61 (t, J=6.6 Hz, 2H, CH₂-Cl), 4.44 (q, J=7.2 Hz, 2H, OCH₂), 6.58 (s, 1H, CH), 11.68 (s, 1H, OH). IR (neat, cm⁻¹): $\tilde{\nu} = 2969$ (m), 1654 (s), 1614 (m), 1453 (m), 1401 (s), 1317 (m), 1264 (s), 1171 (s), 1073 (m), 1024 (m), 816 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=217 (4.44), 254 (4.04), 316 (3.64) nm. MS (EI, 70 eV): m/z (%)=300 $(M^{+}[^{37}Cl], 3), 298 (M^{+}[^{35}Cl], 11), 252 (15), 217 (100),$ 189 (14), 133 (9), 70 (10), 28 (29). Anal. Calcd for C₁₆H₂₃ClO₃ (298.805): C, 64.31; H, 7.76. Found: C, 64.24; H, 9.30.

4.2.6. Ethyl 3-(3'-chloroisobutyl)-2-hydroxy-4,5,6-trimethylbenzoate (3f). The synthesis of **3f** has been previously reported.⁹ Starting with **1b** (1.09 g, 3.0 mmol), **5a** (0.56 g, 3.0 mmol), and TiCl₄ (0.56 g, 3.0 mmol) in CH₂Cl₂ (10 mL), **3f** was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (0.398 g, 44%).

4.2.7. Ethyl 3-(3-chloro-2-methylpropyl)-2-hydroxy-4,6-dimethylbenzoate (3g). Starting with 1b (1.46 g, 4.0 mmol), TiCl₄ (0.75 g, 4.0 mmol), and **5b** (0.69 g, 4.0 mmol) in CH₂Cl₂ (10 mL), **3g** was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (520 mg, 46%). ¹H NMR (CDCl₃, 300 MHz): δ=1.05 (d, J=6.7 Hz, 3H, CH₃), 1.42 (t, J=7.1 Hz, 3H, CH₃), 2.23 (m, 1H, CH), 2.27 (s, 3H, CH₃), 2.49 (s, 3H, CH₃), 2.59-2.79 (m, J=24, 6.9 Hz, 2H, CH₂), 3.42-3.56 (dq, J=7.0 Hz, 2H, CH₂-Cl), 4.43 (q, J=7.2 Hz, 2H, OCH₂), 6.55 (s, 1H, CH), 11.78 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =15.3, 18.9, 21.2, 24.9 (CH₃), 31.8, 36.8 (CH), 52.5, 62.5 (CH₂), 109.8, 124.6 (C), 125.9 (CH), 138.4, 143.6, 161.4, 172.3 (C). IR (neat, cm^{-1}): $\tilde{\nu} = 2959$ (m), 2933 (m), 1654 (s), 1618 (m), 1449 (m), 1397 (m), 1268 (s), 1174 (m), 1097 (m), 1042 (m), 846 (m), 808 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=216 (4.45), 254 (4.02), 315 (3.62) nm. MS (EI, 70 eV): m/z (%)=286 (M⁺[³⁷Cl], 1.4), 284 (M⁺[³⁵Cl], 8), 203 (57), 194 (22), 161 (40), 148 (32), 147 (76), 120 (20), 91 (20), 32 (23), 28 (100). Anal. Calcd for C₁₅H₂₁ClO₃ (284.778): C, 63.25; H, 7.14. Found: C, 62.62; H, 7.49.

4.2.8. Ethyl 3-(3-chloro-2-methylpropyl)-4,6-diethyl-2hydroxybenzoate (3h). Starting with 1b (1.82 g, 5.0 mmol), TiCl₄ (0.95 g, 5.0 mmol), and **5d** (1.0 g, 5.0 mmol) in CH₂Cl₂ (10 mL), **3h** was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (0.820 g, 53%). ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.07$ (d, J = 6.8 Hz, 3H, CH₃), 1.19 (m, J=7.1 Hz, 6H, $2\times$ CH₃), 1.45 (t, J=7.1 Hz, 3H, CH₃), 2.28 (m, J=4.5 Hz, 1H, CH), 2.62 (m, J=7.0 Hz, 2H, CH₂), 2.75 (q, J=7.0 Hz, 2H, CH₂), 2.91 (q, J=7.3 Hz, 2H, CH₂), 3.51 (dq, J=6.8, 5.0 Hz, 2H, CH₂-Cl), 4.44 (q, *J*=7.1 Hz, 2H, OCH₂), 10.77 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =14.4, 15.5, 16.7, 18.3 (CH₃), 26.6, 30.1, 31.8 (CH₂), 36.5 (CH), 51.9, 61.8 (CH₂), 109.1 (C), 121.9 (CH), 123.9, 144.9, 149.7, 161.3, 172.1 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 2972$ (s), 2877 (s), 1654 (s), 1613 (m), 1564 (m), 1460 (s), 1399 (s), 1376 (s), 1315 (s), 1267 (s), 1171 (s), 1071 (m), 946 (m), 867 (m), 813 (m), 725 (m). UVvis (CH₃CN, nm): λ_{max} (log ε)=217 (4.48), 255 (4.05), 317 (3.64) nm. MS (EI, 70 eV): m/z (%)=314 (M⁺[³⁷Cl], 2), 312 (M⁺[³⁵Cl], 9), 232 (43), 231 (100), 190 (12), 189 (51), 176 (29), 133 (13), 28 (25). HRMS (ESI): calcd for C₁₇H₂₅ClO₃ ([M+1]⁺): 315.15410 [³⁷Cl], 313.15705 [³⁵Cl]; found: 315.15432 [³⁷Cl], 313.15664 [³⁵Cl].

4.2.9. Ethyl 3-(3-chloropropyl)-5,6,7,8-tetrahydro-2hydroxynaphthalene-1-carboxylate (3i). Starting with 1a (2.8 g, 8.0 mmol), TiCl₄ (1.5 g, 8.0 mmol), and **5e** (1.59 g, 8.0 mmol) in CH₂Cl₂ (20 mL), 3i was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.72 g, 33%). ¹H NMR (CDCl₃, 300 MHz): δ =1.42 (t, J=7.1 Hz, 3H, CH₃), 1.74 (m, J=3.3 Hz, 4H, 2×CH₂), 2.11 (quint, J=6.9 Hz, 2H, CH₂), 2.69 (m, 2H, CH₂), 2.75 (m, J=7.0 Hz, 2H, CH₂), 2.97 (m, 2H, CH₂), 3.55 (t, J=6.7 Hz, 2H, CH₂-Cl), 4.43 (q, J=7.1 Hz, 2H, OCH₂), 7.01 (s, 1H, CH), 11.18 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.4 (CH₃), 22.5, 23.6, 27.5, 29.6, 29.9, 32.2, 44.9, 61.6 (CH₂), 115.3, 126.2, 128.0 (C), 136.4 (CH), 137.2, 155.3, 172.2 (C). IR (KBr, cm^{-1}): $\tilde{\nu} = 2934$ (s), 2860 (m), 1653 (s), 1431 (s), 1373 (s), 1316 (s), 1283 (s), 1159 (m), 1023 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=213 (4.41), 252 (3.99), 324 (3.80) nm. MS (EI, 70 eV): m/z (%)=298 (M⁺[³⁷Cl], 7), 296 (M⁺[³⁵Cl], 25), 250 (56), 215 (100), 188 (42), 160 (10), 114 (9), 91 (10), 28 (7). HRMS (ESI): calcd for C₁₆H₂₂ClO₃ ([M+1]⁺): 299.12279 [³⁷Cl], 297.12574 [³⁵Cl]; found: 299.12179 [³⁷Cl], 297.12495 [³⁵Cl]. Anal. Calcd for C₁₆H₂₂ClO₃ (297.797): C, 64.85; H, 7.14. Found: C, 64.58: H. 7.35.

4.2.10. Ethyl 3-(3-chloropropyl)-5,6,7,8-tetrahydro-2hydroxy-4-methylnaphthalene-1-carboxylate (3j). Starting with **1a** (1.40 g, 4.0 mmol), TiCl₄ (0.72 g, 4.0 mmol), and 5f (0.85 g, 4.0 mmol) in CH₂Cl₂ (15 mL), 3j was isolated after chromatography (silica gel, n-hexane/EtOAc = 30:1) as a colorless oil (0.42 g, 34%). ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.41$ (t, J = 7.1 Hz, 3H, CH₃), 1.68 (m, J=2.5 Hz, 2H, CH₂), 1.76 (m, J=2.0 Hz, 2H, CH₂), 1.98 (quint, J=6.8 Hz, 2H, CH₂), 2.21 (s, 3H, CH₃), 2.58 (t, J=6.5 Hz, 2H, CH₂), 2.86 (m, J=7.0 Hz, 2H, CH₂), 2.98 (t, J=6.2 Hz, 2H, CH₂), 3.61 (t, J=6.7 Hz, 2H, CH₂-Cl), 4.42 (q, J=7.1 Hz, 2H, OCH₂), 11.23 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =14.2, 15.7 (CH₃), 22.8, 23.0, 23.9, 27.9, 30.3, 32.2, 45.3, 61.4 (CH₂), 110.2, 125.2, 127.4, 136.9, 142.4, 158.1, 172.2 (C). IR (neat, cm^{-1}): $\tilde{\nu} = 3416$ (w), 2931 (s), 2863 (m), 1650 (s), 1598 (m), 1434 (s), 1401 (s), 1375 (s), 1316 (s), 1275 (s), 1241 (s), 1202 (s), 1149 (m), 1035 (m), 804 (m), 651 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=216.5 (4.36), 257.9 (3.98), 320.7 (3.59) nm. MS (EI, 70 eV): m/z (%)=312 (M⁺[³⁷Cl], 5), 310 (M⁺[³⁵Cl], 17), 264 (27), 230 (16), 229 (100), 202 (15), 28 (13). Anal. Calcd for C₁₇H₂₃ClO₃ (310.816): C, 65.69; H, 7.46. Found: C, 65.39; H, 7.78.

4.2.11. Ethyl-2-(3-chloropropyl)-9,10-dihydro-3hydroxy-1-methylphenanthrene-4-carboxylate (3k). Starting with 1a (2.8 g, 8.0 mmol), 5g (2.08 g, 8.0 mmol), and TiCl₄ (1.52 g, 8.0 mmol) in CH₂Cl₂ (20 mL), 3k was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 30:1) as a colorless oil (0.78 g, 27%). ¹H NMR (CDCl₃, 300 MHz): δ =1.00 (t, J=7.1 Hz, 3H, CH₃), 2.03 (quint, 7.5 Hz, 2H, CH₂), 2.32 (s, 3H, CH₃), 2.65 (t, J=5.6 Hz, 2H, CH₂), 2.81 (t, J=6.7 Hz, 2H, CH₂), 2.92 (t, J=6.2 Hz, 2H, CH₂), 3.64 (t, J=7.7 Hz, 2H, CH₂-Cl), 4.16 (q, J=7.1 Hz, 2H, OCH₂), 7.06–7.09 (dd, 1H, CH of Ar), 7.12-7.18 (m, 2H, 2×CH of Ar), 7.21-7.24 (dd, 1H, CH of Ar), 9.95 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =13.4, 15.7 (CH₃), 24.2, 25.7, 29.2, 31.1, 45.2, 61.3 (CH₂), 109.0 (C), 125.4 (CH), 126.7 (C), 126.8, 126.9, 129.2 (CH), 130.6, 134.6 (C), 137.6 (2C), 139.7, 156.5, 172.2 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 3293$ (w), 2956 (m), 1662 (s), 1592 (m), 1443 (m), 1397 (m), 1373 (m), 1313 (s), 1246 (s), 1188 (s), 1162 (m), 1071 (m), 1029 (m), 765 (s). UV-vis (CH₃CN, nm): λ_{max} (log ε)=204 (4.48), 232 (4.40), 280 (3.94), 341 (3.89) nm. MS (EI, 70 eV): m/z (%)=358 (M⁺[³⁵Cl], 6), 344 (6), 312 (5), 277 (16), 263 (32), 242 (24), 196 (13), 161 (100), 134 (41), 105 (19), 77 (22), 28 (39). Anal. Calcd for C₂₁H₂₃ClO₃ (358.859): C, 70.28; H, 6.46. Found: C, 70.44; H, 6.11.

4.3. General procedure for the preparation of salicylates (3l,m)

The synthesis of **3**l,**m** has been previously reported.⁹ To a stirred CH₂Cl₂ solution (100 mL) of 1,1-diacetylcyclopropane (**6**) (1.1 mmol) and 1,3-bis-silyl enol ether **1a** (1.6 mmol) was added TiCl₄ (2.0 mmol in 2 mL CH₂Cl₂) at -78 °C under argon atmosphere in the presence of molecular sieves (4 Å, 1.0 g). The temperature of the reaction mixture was allowed to rise to 20 °C during 6 h. The solution was stirred for additional 6 h at 20 °C. The reaction mixture was filtered and the filtrate was poured into an aqueous solution of HCl (10%, 100 mL). The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3× 100 mL). The combined organic layers were dried (Na₂SO₄), filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, *n*-hexane/EtOAc) to give **3**l,**m**.

4.3.1. Ethyl 5-(2-chloroethyl)-3-(3-chloropropyl)-2-hydroxy-4,6-dimethylbenzoate (3l). The synthesis of **3l** has been previously reported.⁹ Starting with CH₂Cl₂ (250 mL), **6** (0.48 g, 3.8 mmol), **1a** (2.0 g, 5.7 mmol), and TiCl₄ (2.16 g, 11.4 mmol), **3l** was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 25:1) as a colorless solid (0.672 g, 53%).

4.3.2. Ethyl 5-(2-bromoethyl)-3-(3-chloropropyl)-2-hydroxy-4,6-dimethylbenzoate (3m). The synthesis of **3m** has been previously reported.⁹ Starting with **1a** (1.58 g, 4.5 mmol), **6** (0.38 g, 3.0 mmol), TiBr₄ (2.21 g, 6.0 mmol), and CH₂Cl₂ (200 mL), **3m** was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.397 g, 35%).

4.4. General procedure for the synthesis of 5-(2-hydroxybenzoyl)salicylates (10a–h)

To the 3-formylchromone **8a–e** (1.0 equiv) was added Me₃SiOTf (0.3 equiv) at 20 °C. After stirring for 10 min, CH₂Cl₂ (8 mL) was added, the solution was cooled to 0 °C and the 1,3-bis-silyl enol ether **1a,b** (1.3 equiv) was added. The mixture was stirred for 12 h at 20 °C and was

subsequently poured into an aqueous solution of hydrochloric acid (10%). The organic and the aqueous layer were separated and the latter was extracted with Et₂O (3×80 mL). The combined organic layers were washed with water, dried (Na₂SO₄), filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, *n*-hexane/EtOAc = $10:1 \rightarrow 3:1$).

4.4.1. Ethyl 3-(3-chloropropyl)-5-(2-hydroxybenzoyl)salicylate (10a). Starting with 8a (268 mg, 1.54 mmol), Me₃SiOTf (103 mg, 0.46 mmol), and 1.3-bis-silvl enol ether 1a (703 mg, 2.00 mmol). 10a was isolated as a vellow solid (229 mg, 41%), mp=107 °C, ¹H NMR (300 MHz, CDCl₃); $\delta = 1.41$ (t, J = 7.1 Hz, 3H, OCH₂CH₃), 2.15 (m, 2H, CH₂CH₂CH₂), 2.90 (t, J=7.1 Hz, 2H, ArCH₂), 3.58 (t, J=6.5 Hz, 2H, CH₂-Cl), 4.44 (q, J=7.2 Hz, 2H, OCH₂CH₃), 6.92 (m, 1H, Ar), 7.09 (dd, J=8.4, 1.0 Hz, 1H, Ar), 7.53 (m, 1H, Ar), 7.59 (dd, J=8.0, 1.5 Hz, 1H, Ar), 7.40 (d, J=2.3 Hz, 1H, Ar), 8.18 (d, J=2.3 Hz, 1H, Ar), 11.65 (s, 1H, OH), 11.88 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): $\delta = 14.1$ (CH₃), 27.2, 31.6 (CH₂), 44.4 (CH₂Cl), 62.1 (OCH₂CH₃), 111.9 (C), 118.5, 118.7 (CH), 119.0, 128.4, 129.5 (C), 130.5, 132.9, 136.1, 136.6 (CH), 162.9, 163.0 (C-OH), 169.9, 199.2 (C=O). IR (KBr): $\tilde{\nu} = 3329$ (m), 3095 (m), 3070 (m), 2991 (m), 2963 (m), 2938 (m), 1675 (s), 1624 (s), 1590 (s), 1483 (s), 1450 (s), 1407 (s), 1381 (s), 1348 (s), 1328 (s), 1289 (s), 1264 (s), 1237 (s), 1192 (s), 1158 (s), 1134 (w), 1023 (m), 807 (w), 770 (s), 738 (m), 706 (m), 659 (w) cm⁻¹. UV-vis (CH₃CN): λ_{max} (log ε): 316 (3.93), 289 (3.99), 240 (4.28), 214 (4.47) nm. MS (EI, 70 eV): m/z (%)=362 (M⁺, 64), 317 (4), 281 (67), 252 (19), 242 (24), 197 (6), 161 (10), 121 (100), 93 (9). HRMS (FT-ICR): calcd for C₁₉H₁₉O₅Cl ([M+1]⁺): 363.09938; found: 363.09970. Anal. Calcd for C₁₉H₁₉ClO₅: C, 62.90; H, 5.28. Found: C, 62.72; H, 5.51.

4.4.2. Ethyl 3-(3-chloropropyl)-2-hydroxy-5-(2-hydroxy-5-methylbenzoyl)benzoate (10b). Starting with 8b (376 mg, 2.00 mmol), Me₃SiOTf (133 mg, 0.60 mmol), and 1,3-bis-silyl enol ether 1a (917 mg, 2.60 mmol), 10b was isolated as a yellow solid by column chromatography with *n*-hexane/EtOAc = 25:1 (410 mg, 54%). ¹H NMR (300 MHz, CDCl₃): δ=1.43 (t, J=7.1 Hz, 3H, OCH₂CH₃), 2.16 (m, J=6.6 Hz, 2H, CH₂CH₂CH₂Cl), 2.28 (s, 3H, CH₃), 2.90 (t, J=7.1 Hz, 2H, ClCH₂CH₂CH₂), 3.58 (t, J=6.5 Hz, 2H, CH₂CH₂CH₂Cl), 4.46 (q, J=7.2 Hz, 2H, OCH₂CH₃), 7.00 (d, J=2.3 Hz, 1H, Ar), 7.26 (d, J=2.0 Hz, 1H, Ar), 7.36 (dd, J=1, 2 Hz, 1H, Ar), 7.74 (d, J=2.0 Hz, 1H, Ar), 8.19 (d, J=2.3 Hz, 1H, Ar), 11.63 (s, 1H, OH), 11.68 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): δ =14.2, 20.5 (CH₃), 27.2, 31.5, 44.3, 62.0 (CH₂), 112.1 (C), 118.3 (CH), 118.8, 127.9, 128.6, 129.4 (C), 130.6, 132.7, 136.7, 137.2 (CH), 160.0, 163.0, 170.1, 199.2 (C). MS (EI, 70 eV): m/z (%)=378 (M⁺[³⁷Cl ³⁵Cl], 18), 376 (M⁺[³⁵Cl ³⁵Cl], 55), 340 (34), 295 (55), 206 (31), 135 (100), 44 (72). IR (KBr): $\tilde{\nu} = 2990$ (w), 1674 (s), 1631 (s), 1583 (s), 1484 (m), 1406 (s), 1378 (s), 1348 (s), 1290 (s), 1236 (s), 1177 (s), 1023 (m), 786 (m), 705 (m) cm⁻¹. UV-vis (CH₃CN): λ_{max} (log ε)=214.9 (4.45), 240.3 (4.29), 285.3 (3.99), 343.5 (3.74) nm. Anal. Calcd for C₂₀H₂₁O₅Cl: C, 63.74; H, 5.62. Found: C, 63.60; H, 5.72.

4.4.3. Ethyl 3-(3-chloropropyl)-2-hydroxy-5-(2-hydroxy-5-ethylbenzoyl)benzoate (10c). Starting with 8c (505 mg, 2.50 mmol), Me₃SiOTf (167 mg, 0.75 mmol), and 1,3-bissilyl enol ether 1a (1.147 mg, 3.25 mmol), 10c was isolated as a yellow solid by column chromatography with *n*-hexane/ EtOAc = 25:1 (472 mg, 48%). ¹H NMR (300 MHz, CDCl₃): $\delta = 1.20$ (t, J=7.6 Hz, 3H, CH₃CH₂), 1.42 (t, J=7.2 Hz, 3H, OCH₂CH₃), 2.15 (m, J=6.4 Hz, 2H, CH₂CH₂CH₂Cl), 2.57 $(q, J=7.5 \text{ Hz}, 2\text{H}, CH_3CH_2), 2.89$ (t, J=7.2 Hz, 2H,ClCH₂CH₂CH₂), 3.59 (t, J=6.5 Hz, 2H, CH₂CH₂CH₂Cl), 4.45 (g, J=7.2 Hz, 2H, OCH₂CH₃), 7.02 (d, J=8.4 Hz, 1H, Ar), 7.35–7.41 (m, J=2.1 Hz, 2H, Ar), 7.77 (t, J=1.5 Hz, 1H. Ar), 8.19 (d. J=2.3 Hz, 1H. Ar), 11.64 (s. 1H. OH), 11.68 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): $\delta = 14.1, 15.9 (CH_3), 27.2, 27.9, 31.7, 44.4, 62.0 (CH_2),$ 111.9 (C), 118.3, 118.8 (CH), 128.5, 129.6 (C), 130.8, 131.6 (CH), 134.4 (C), 136.1, 136.7 (CH), 161.1, 163.1, 170.1, 199.1 (C). IR (KBr): $\tilde{\nu} = 3167$ (br), 2961 (m), 1675 (s), 1629 (m), 1588 (s), 1476 (m), 1342 (m), 1290 (m), 1254 (s), 1200 (s), 1166 (m), 1023 (m), 841 (m) cm⁻ UV–vis (CH₃CN): λ_{max} (log ε)=251.0 (4.42), 239.6 (4.26), 287.9 (3.96), 344.5 (3.71) nm. MS (EI, 70 eV): m/z $(\%)=392 (M^{+}[^{37}Cl], 8), 390 (M^{+}[^{35}Cl], 29), 310 (45), 226$ (38), 225 (100), 148 (61), 147 (51), 133 (19), 74 (17), 28 (71). HRMS (ESI): calcd for $C_{21}H_{23}O_5Cl$: 390.12340; found: 390.12216.

4.4.4. Ethyl 3-(3-chloropropyl)-2-hydroxy-5-(2-hydroxy-5-chlorobenzoyl)benzoate (10d). Starting with 8d (522 mg, 2.50 mmol), Me₃SiOTf (167 mg, 0.75 mmol), and 1,3-bis-silyl enol ether 1a (1.147 g, 3.25 mmol), 10d was isolated as vellow solid by column chromatography with *n*-hexane/EtOAc = 25:1 (507 mg, 51%). ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3): \delta = 1.42 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}, \text{OCH}_2\text{CH}_3),$ 2.16 (m, J=6.5 Hz, 2H, CH₂CH₂CH₂Cl), 2.92 (t, J=7.0 Hz, 2H, ClCH₂CH₂CH₂), 3.59 (t, J=6.5 Hz, 2H, CH₂CH₂CH₂Cl), 4.48 (q, J=7.2 Hz, 2H, OCH₂CH₃), 7.05 (d, J=8.5 Hz, 1H, Ar), 7.35-7.41 (dd, J=2.6 Hz, 6.2 Hz, 1H, Ar), 7.58 (d, J=2.6 Hz, 1H, Ar), 7.75 (t, J=1 Hz, 1H, Ar), 8.18 (d, J=2.3 Hz, 1H, Ar), 11.70 (s, 1H, OH), 11.74 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): $\delta = 14.1$ (CH₃), 27.3, 31.6, 44.3, 62.2 (CH₂), 112.1, 119.7 (C), 120.1 (CH), 123.5, 127.8, 130.0 (C), 130.7, 131.9, 135.9, 136.4 (CH), 161.4, 163.5, 169.9, 198.2 (C). IR (KBr): $\tilde{\nu} = 3089$ (br), 2956 (w), 1675 (m), 1630 (m), 1464 (m), 1335 (m), 1256 (m), 1206 (m), 1017 (w), 843 (m) cm⁻¹. UV-vis (CH₃CN): λ_{max} (log ε)=218.9 (4.39), 293.1 (3.84) nm. MS (EI, 70 eV): m/z (%)=398 (M⁺[³⁷Cl ³⁵Cl], 4), 390 (M⁺[³⁵Cl ³⁵Cl], 10), 363 (4), 320 (8), 291 (40), 275 (19), 219 (33), 217 (31), 203 (18), 146 (20), 129 (29), 74 (100), 28 (59). Anal. Calcd for C19H18O5Cl2: C, 57.63; H, 4.58. Found: C, 56.75; H, 5.43.

4.4.5. Ethyl 3-(3-chloropropyl)-2-hydroxy-5-(2-hydroxy-5-chloro-3-methylbenzoyl)benzoate (10e). Starting with **8e** (556 mg, 2.50 mmol), Me₃SiOTf (167 mg, 0.75 mmol), and 1,3-bis-silyl enol ether **1a** (1.147 mg, 3.25 mmol), **10e** was isolated as yellow solid by column chromatography with *n*-hexane/EtOAc = 25:1 (482 mg, 47%). ¹H NMR (300 MHz, CDCl₃): δ =1.43 (t, *J*=7.2 Hz, 3H, OCH₂CH₃), 2.16 (m, *J*=6.5 Hz, 2H, CH₂CH₂CH₂Cl), 2.42 (s, 3H, CH₃), 2.92 (t, *J*=7.3 Hz, 2H, CICH₂CH₂CH₂), 3.59 (t, *J*=6.5 Hz, 2H, CH₂CH₂Cl), 4.48 (q, *J*=7.1 Hz, 2H, CH₂CH₂CH), 2.49

OCH₂CH₃), 6.99 (d, *J*=1.0 Hz, 1H, Ar), 7.56 (s, 1H, Ar), 7.73 (dd, *J*=1, 2 Hz, 1H, Ar), 8.17 (d, *J*=2.3 Hz, 1H, Ar), 11.67 (s, 1H, OH), 11.77 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): δ =14.1, 20.8 (CH₃), 27.3, 31.6, 44.3, 62.1 (CH₂), 112.1, 117.9 (C), 120.5 (CH), 124.1, 127.9, 129.9 (C), 130.5, 132.3, 136.4 (CH), 145.4, 161.4, 163.3, 169.9, 197.9 (C). IR (KBr): $\tilde{\nu}$ = 3110 (br), 2957 (m), 1678 (s), 1626 (m), 1587 (s), 1471 (m), 1381 (m), 1340 (s), 1264 (s), 1242 (s), 1181 (s), 1022 (m), 843 (s) cm⁻¹. UVvis (CH₃CN): λ_{max} (log ε)=218.9 (4.39), 293.1 (3.84) nm. MS (EI, 70 eV): *m/z* (%)=413 (M⁺[³⁷Cl ³⁵Cl], 20), 411 (M⁺[³⁵Cl ³⁵Cl], 36), 371 (11), 329 (26), 219 (35), 217 (39), 169 (49), 129 (24), 74 (100), 29 (19). HRMS (ESI): calcd for C₂₀H₂₀O₅Cl₂: 410.06878; found: 410.06721.

4.4.6. Ethyl 3-(3-chloro-2-methylpropyl)-2-hydroxy-5-(2-hydroxybenzoyl)benzoate (10f). Starting with formylchromone 8a (348 mg, 2.0 mmol), Me₃SiOTf (133 mg, 0.60 mmol), and 1,3-bis-silvl enol ether 1b (949 mg, 2.6 mmol), 10f was isolated by column chromatography (silica gel, *n*-hexane/EtOAc = 25:1) as a yellow solid (324 mg, 43%). ¹H NMR (300 MHz, CDCl₃): δ =1.08 (d, J=6.7 Hz, 3H, $CH_3(CH)CH_2$), 1.42 (t, J=7.2 Hz, 3H, OCH₂CH₃), 2.38 (m, J=5.7 Hz, 1H, CH₃(CH)CH₂), 2.69 $(q, J=7.2 \text{ Hz}, 1\text{H}, CH_3(CH)CH_2), 2.87 (q, J=7.1 \text{ Hz}, 1\text{H}, 1\text{H})$ CH₃(CH)CH₂), 3.43–3.57 (qq, J=5.4, 9.2 Hz, 2H, CH₃(CH)CH₂Cl), 4.46 (q, J=7.1 Hz, 2H, OCH₂CH₃), 6.89–6.94 (td, J=6.3, 1.0 Hz, 1H, Ar), 7.08–7.10 (dd, J=7.6, 1.0 Hz, 1H, Ar), 7.49–7.56 (td, J=7.0, 2.0 Hz, 1H, Ar), 7.59–7.62 (dd, J=6.3, 2.0 Hz, 1H, Ar), 7.72 (d, J=2.2 Hz, 1H, Ar), 8.20 (d, 2.2 Hz, 1H, Ar), 11.66 (s, 1H, OH), 11.89 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): $\delta = 14.2, 17.7$ (CH₃), 34.4 (CH₂), 34.9 (CH), 50.6, 62.1 (CH₂), 112.1 (C), 118.5, 118.7 (CH), 119.1, 128.4, 128.8 (C), 130.6, 132.9, 136.2, 137.4 (CH), 163.0, 163.2, 170.1, 199.3 (C). UV-vis (CH₃CN): λ_{max} (log ε)=214.9 (4.46), 240.2 (4.28), 289.6 (3.99), 317.2 (3.94) nm. IR (KBr): $\tilde{\nu} = 3418$ (br), 2960 (w), 1675 (s), 1624 (s), 1587 (s), 1482 (m), 1458 (m), 1348 (s), 1296 (s), 1263 (s), 1240 (s), 1180 (s), 766 (m) cm⁻¹. MS (EI, 70 eV): m/z (%)=378 (M⁺[³⁷Cl], 1), 376 (M⁺[³⁵Cl], 5), 295 (8), 253 (8), 121 (14), 32 (24), 28 (100). Anal. Calcd for C₂₀H₂₁O₅Cl: C, 63.75; H, 5.62. Found: C, 63.52; H, 5.65.

4.4.7. Ethyl 3-(3-chloro-2-methylpropyl)-2-hydroxy-5-(2-hydroxy-5-methylbenzoyl)benzoate (10g). Starting with **8b** (376 mg, 2.0 mmol), Me₃SiOTf (133 mg, 0.60 mmol), and 1,3-bis-silyl enol ether **1b** (948 mg, 2.60 mmol), 10g was isolated as yellow solid by column chromatography with *n*-hexane/EtOAc = 25:1 (320 mg, 41%). ¹H NMR (300 MHz, CDCl₃): δ =1.09 (d, J=6.7 Hz, 3H, $CH_3(CH)CH_2$, 1.44 (t, J=7.2 Hz, 3H, CH_3CH_2O), 2.28 (s, 3H, CH₃), 2.38 (m, J=5.5 Hz, 1H, CH₃(CH)CH₂), 2.69 (q, J=6.2 Hz, 1H, CH₃(CH)CH₂), 2.87 (q, J=6.5 Hz, 1H, CH₃(CH)CH₂), 3.45–3.58 (qq, J=5.2, 9.0 Hz, 2H, CH₃(CH)CH₂Cl), 4.46 (q, J=7.1 Hz, 2H, CH₃CH₂O), 7.00 (d, J=8.3 Hz, 1H, Ar), 7.31–7.38 (m, J=1.0, 2.0 Hz, 2H, Ar), 7.71 (d, J=2.2 Hz, 1H, Ar), 7.74 (d, J=2.0 Hz, 1H, Ar), 8.21 (d, J=2.3 Hz, 1H, Ar), 11.63 (s, 1H, OH), 11.68 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): $\delta = 14.2, 17.8, 20.5$ (CH₃), 30.3 (CH), 34.4 (CH₂), 34.9 (CH₃), 50.6, 62.1 (CH₂), 112.1 (C), 118.3 (CH), 118.8, 127.9, 128.5 (C), 130.6, 132.7, 137.2, 137.5 (CH), 160.9, 163.1, 170.1, 199.3 (C). IR (KBr): $\tilde{\nu} = 2962$ (w), 1676 (s), 1630 (s), 1586 (s), 1482 (m), 1349 (s), 1291 (s), 1265 (s), 1204 (s), 1173 (m), 791 (m) cm⁻¹. UV–vis (CH₃CN): λ_{max} (log ε)=213.3 (4.47), 240.6 (4.29), 287.8 (3.98), 345.1 (3.73) nm. MS (EI, 70 eV): *m/z* (%)=326 (M⁺, 90), 175 (100), 134 (91), 77 (15), 28 (29). HRMS (ESI): calcd for C₂₁H₂₃O₅Cl: 390.12340; found: 390.12286.

4.4.8. Ethyl 3-(3-chloro-2-methylpropyl)-2-hydroxy-5-(2-hydroxy-5-chlorobenzoyl)benzoate (10h). Starting with 8d (417 mg, 2.00 mmol), Me₃SiOTf (133 mg, 0.60 mmol), and 1,3-bis-silvl enol ether **1b** (948 mg, 2.6 mmol), 10h was isolated as yellow solid by column chromatography with *n*-hexane/EtOAc=25:1 (410 mg, 38%). ¹H NMR (300 MHz, CDCl₃): $\delta = 1.08$ (d, J = 6.7 Hz, 3H, CH₃(CH)CH₂), 1.43 (t, J=7.1 Hz, 3H, OCH₂CH₃), 2.37 (m, J=5.4 Hz, 1H, CH₃(CH)CH₂), 2.69 (q, J=7.0 Hz, 1H, $CH_3(CH)CH_2$), 2.88 (q, J=7.0 Hz, 1H, $CH_3(CH)CH_2$), 3.44-3.57 (qq, J=5.4, 8.0 Hz, 2H, CH₃(CH)CH₂Cl), 4.47 (q, J=7.2 Hz, 2H, OCH₂CH₃), 7.06 (d, J=8.9 Hz, 1H, Ar), 7.44–7.48 (m, J=2.5, 6.3 Hz, 1H, Ar), 7.57 (d, J=2.0 Hz, 1H, Ar), 7.71 (d, J=2.2 Hz, 1H, Ar), 8.19 (d, J=2.2 Hz, 1H, Ar), 11.69 (s, 1H, OH), 11.73 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): δ =14.1, 17.7 (CH₃), 34.4 (CH₂), 34.9 (CH), 50.6, 62.2 (CH₂), 112.2, 119.7 (C), 120.1 (CH), 123.4, 127.5, 129.1 (C), 130.7, 131.9, 135.9, 137.2 (CH), 161.4, 163.5, 169.9, 198.1 (C). IR (KBr): $\tilde{\nu} = 3109$ (br), 2970 (w), 1674 (s), 1629 (s), 1593 (s), 1464 (s), 1378 (m), 1347 (s), 1320 (s), 1287 (s), 1254 (s), 1231 (s), 1177 (s), 737 (m) cm⁻¹. UV-vis (CH₃CN): λ_{max} $(\log \varepsilon) = 218.6$ (4.52), 294.2 (3.95), 343.1 (3.78) nm. MS (EI, 70 eV): m/z (%)=413 (M⁺[³⁷Cl ³⁵Cl], 7), 412 (31), 411 (M⁺[³⁵Cl ³⁵Cl], 11), 410 (47), 374 (34), 287 (12), 220 (100), 155 (49). HRMS (ESI): calcd for $C_{20}H_{20}O_5Cl_2$: 410.06878; found: 410.06794. Anal. Calcd for C₂₀H₂₀O₅Cl₂: C, 58.41; H, 4.90. Found: C, 58.45; H, 4.89.

4.4.9. 2-Bromo-4-(3-chloropropyl)-1,3-dihydroxyanthracene-9,10-dione (13). A THF solution (50 mL) of 1a (2.81 g, 8.0 mmol) and 2-bromonaphthalene-1,4-dione (12) (0.95 g, 4.0 mmol) was stirred at -78 °C for 1 h. The solution was allowed to warm to 20 °C during 14 h. To the solution was added hydrochloric acid (10 mL, 6 M). The THF was removed in vacuo and the residue was washed with water and extracted with CH_2Cl_2 (3×50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the solvent of the filtrate was removed in vacuo. The residue was purified by column chromatography (silica gel, n-hexane/ EtOAc = 20:1) to give **13** as a yellowish solid (0.375 g, 30%). ¹H NMR (CDCl₃, 300 MHz): δ =2.14 (m, J=6.9, 1.5 Hz, 2H, CH₂), 3.36 (m, J=5.7 Hz, 2H, CH₂), 3.74 (t, J=6.8 Hz, 2H, CH₂-Cl), 6.59 (s, 1H, OH), 7.71-7.83 (m, 2H, 2×CH of Ar), 8.22–8.29 (m, 2H, 2×CH of Ar), 14.44 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =25.1, 31.9, 45.3 (CH₂), 105.4, 110.6 (C), 126.3, 127.3 (CH), 127.5, 130.4, 132.1 (C), 134.5 (CH), 134.6 (C), 135.2 (CH), 160.5, 161.1, 184.2, 187.1 (C). IR (KBr, cm^{-1}): $\tilde{\nu} = 3435$ (s), 1667 (s), 1626 (s), 1586 (s), 1439 (s), 1393 (s), 1358 (s), 1279 (s), 1183 (s), 1150 (s), 1013 (m), 838 (m), 732 (s), 628 (m). UV-vis (CH₃CN, nm): λ_{max} $(\log \varepsilon)=206.7$ (4.32), 248.9 (4.37), 272.5 (4.37), 338.6 (3.51), 408.4 (3.77) nm. MS (EI, 70 eV): m/z (%)=398 $(M^{+}[^{81}Br \ ^{37}Cl], 20), 397 (12), 396 (M^{+}[^{81}Br \ ^{35}Cl],$

 $\begin{array}{l} M^+[^{79}Br \ ^{37}Cl], \ 100), \ 395 \ (8), \ 394 \ (M^+[^{79}Br \ ^{35}Cl], \ 73), \ 331 \\ (85), \ 264 \ (8), \ 210 \ (14), \ 139 \ (34), \ 105 \ (6), \ 77 \ (13), \ 28 \ (40). \\ HRMS \ \ (ESI): \ calcd \ for \ C_{17}H_{12}BrClO_4 \ ([M+1]^+): \\ 396.96562 \ [^{81}Br \ ^{35}Cl], \ 394.96857 \ [^{79}Br \ ^{35}Cl]; \ found: \\ 396.94806 \ [^{81}Br \ ^{35}Cl], \ 394.95052 \ [^{79}Br \ ^{35}Cl]. \ Anal. \ Calcd \\ for \ C_{17}H_{12}BrClO_4 \ (395.632): \ C, \ 51.59; \ H, \ 3.06. \ Found: \ C, \\ 51.86; \ H, \ 3.60. \end{array}$

4.5. General procedure for the synthesis of chromanes (4a–m), (11a–h), and (14)

To a THF solution of **3a–m**, **10a–h**, or **13** and of NaH was added TBAI. After stirring at 20 °C for 20 h, the mixture was concentrated in vacuo and the residue was purified by column chromatography (silica gel, *n*-hexane/EtOAc) to give the product.

4.5.1. Ethyl 3,4-dihydro-2H-chromene-8-carboxylate (4a). Starting with 3a (0.329 g, 1.36 mmol), NaH (0.040 g, 1.66 mmol), and TBAI (0.721 g, 2.21 mmol) in THF (22 mL), 4a was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless oil (0.230 g, 64%). ¹H NMR (CDCl₃, 300 MHz): δ =1.37 (t, J=7.1 Hz, 3H, CH₃), 2.04 (m, J=5.3 Hz, 2H, CH₂), 2.82 (t, J=6.5 Hz, 2H, CH₂), 4.29 (t, J=5.3 Hz, 2H, CH₂), 4.35 (q, J=7.1 Hz, 2H, OCH₂), 6.83 (t, J=7.6 Hz, 1H, CH of Ar), 7.17 (m, J=6.5, 1 Hz, 1H, CH of Ar), 7.61 (dt, J=7.8, 1 Hz, 1H, CH of Ar). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.3 (CH₃), 21.7, 25.1, 60.6, 66.9 (CH₂), 111.1 (CH), 119.6, 123.4 (C), 129.3, 133.7 (CH), 154.9, 166.2 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 2979$ (m), 2937 (m), 1726 (s), 1595 (s), 1473 (s), 1454 (s), 1367 (m), 1298 (s), 1265 (s), 1238 (s), 1176 (s), 1138 (s), 1094 (s), 1055 (s), 958 (m), 878 (m), 761 (s). UV-vis (CH₃CN, nm): λ_{max} (log ε)=209 (4.43), 298 (3.51) nm. MS (EI, 70 eV): m/z (%)=207 ([M+1]⁺, 6), 206 (M⁺, 46), 161 (100), 133 (34), 105 (31), 77 (27), 51 (18), 29 (8). HRMS (FT-ICR): calcd for $C_{12}H_{14}O_3$ ([M+1]⁺): 207.10212; found: 207.10165. Anal. Calcd for C₁₂H₁₄O₃ (206.238): C, 69.89; H, 6.84. Found: C, 69.18; H, 6.75.

4.5.2. Ethyl 3,4-dihydro-5,6,7-trimethyl-2H-chromene-8carboxylate (4b). Starting with 3b (0.307 g, 1.09 mmol), NaH (0.039 g, 1.63 mmol), and TBAI (0.771 g, 2.18 mmol) in THF (20 mL), 4b was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.235 g, 90%), mp=76 °C. ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.36$ (t, J = 7.1 Hz, 3H, CH₃), 2.00 (m, 2H, CH₂), 2.13 (s, 6H, 2×CH₃), 2.17 (s, 3H, CH₃), 2.65 (t, J=6.5 Hz, 2H, CH₂), 4.11 (t, J=5.2 Hz, 2H, CH₂), 4.39 (q, J=7.1 Hz, 2H, OCH₂). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.3, 15.3, 15.5 (CH₃), 17.2, 22.5, 23.2, 60.9, 65.8 (CH₂), 118.6, 121.6, 126.8, 130.9, 136.8, 149.3, 169.4 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 2983$ (m), 2936 (m), 1724 (s), 1581 (m), 1455 (m), 1312 (m), 1277 (s), 1184 (s), 1114 (s), 1084 (m), 1046 (s), 964 (m). UV-vis (CH₃CN, nm): λ_{max} $(\log \varepsilon)=205$ (4.49), 289 (3.43) nm. MS (EI, 70 eV): m/z (%)=249 ([M+1]⁺, 14), 248 (M⁺, 100), 203 (66), 202 (22), 174 (25), 161 (40), 133 (13), 105 (11), 77 (16), 51 (5), 29 (8). HRMS (ESI): calcd for $C_{15}H_{20}O_3$ ([M+1]⁺): 249.14910; found: 249.14908.

4.5.3. Ethyl 5,7-dimethyl-3,4-dihydro-2*H***-chromene-8-carboxylate (4c).** Starting with **3c** (0.059 g, 0.22 mmol),

NaH (0.008 g, 0.33 mmol), and TBAI (0.144 g, 0.44 mmol) in THF (5 mL), 4c was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless oil (0.036 g, 70%). ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.36$ (t, J=7.1 Hz, 3H, CH₃), 2.02 (m, J=4.2, 1.2 Hz, 2H, CH₂), 2.16 (s, 3H, CH₃), 2.21 (s, 3H, CH₃), 2.59 (t, J=6.6 Hz, 2H, CH₂), 4.14 (t, J=5.2 Hz, 2H, CH₂), 4.38 (q, J=7.1 Hz, 2H, OCH₂), 6.75 (s, 1H, CH of Ar). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.3, 18.9, 19.0 (CH₃), 22.0, 22.2, 60.9, 66.1 (CH₂), 118.6, 120.9 (C), 123.1 (CH), 133.1, 138.6, 151.9, 168.7 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 3414$ (m), 2977 (s), 2938 (s), 1716 (s), 1612 (m), 1574 (m), 1457 (s), 1369 (m), 1303 (s), 1273 (s), 1151 (s), 1106 (s), 1056 (s), 959 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=207 (4.48), 285 (3.34) nm. MS (EI, 70 eV): m/z (%)=236 ([M+2]⁺, 1), 235.1 ([M+1]⁺, 12), 234 (M⁺, 87), 189 (100), 161 (31), 132 (20), 103 (7), 77 (12), 28 (17). HRMS (ESI): calcd for C₁₄H₁₉O₃ ([M+1]⁺): 235.13342; found: 235.13286. Anal. Calcd for C₁₄H₁₈O₃ (234.291): C, 71.77; H, 7.74. Found: C, 70.94; H, 7.37.

4.5.4. Ethyl-3,4-dihydro-5,7-dimethyl-6-ethyl-2H-chromene-8-carboxylate (4d). Starting with 3d (0.274 g, 0.92 mmol), NaH (0.033 g, 1.37 mmol), and TBAI (0.600 g, 1.84 mmol) in THF (20 mL), 4d was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless oil (0.198 g, 82%). ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.06$ (t, J = 7.5 Hz, 3H, CH₃), 1.36 (t, J = 7.2 Hz, 3H, CH₃), 2.01 (m, J=6.5 Hz, 2H, CH₂), 2.15 (s, 3H, CH₃), 2.20 (s, 3H, CH₃), 2.56–2.64 (m, J=7.4 Hz, 4H, 2×CH₂), 4.09 (t, J=5.2 Hz, 2H, CH₂), 4.37 (q, J=7.1 Hz, 2H, OCH₂). ¹³C NMR (CDCl₃, 75 MHz): δ_C=13.7, 14.1, 14.6, 16.0 (CH₃), 22.2, 22.3, 23.0, 60.8, 65.7 (CH₂), 118.8, 121.8, 130.2, 132.6, 136.1, 149.2, 169.3 (C). IR (neat, cm⁻¹): $\tilde{\nu} = 3435$ (w), 2968 (s), 2934 (s), 2872 (s), 1728 (s), 1583 (s), 1451 (s), 1372 (m), 1275 (s), 1187 (s), 1115 (s), 1087 (s), 1043 (s), 956 (m), 735 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=207 (4.48), 289 (3.36) nm. MS (EI, 70 eV): m/z (%)=263 ([M+1]⁺, 7), 262 (M⁺, 50), 247 (66), 217 (32), 201 (28), 188 (20), 84 (56), 32 (25), 28 (100).

4.5.5. Ethyl 5,7-diethyl-3,4-dihydro-2H-chromene-8-carboxylate (4e). Starting with 3 (0.330 g, 1.10 mmol), NaH (0.040 g, 1.66 mmol), TBAI (0.721 g, 2.21 mmol) in THF (20 mL), 4e was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless oil (0.230 g, 80%). ¹H NMR (CDCl₃, 300 MHz): δ =1.19 (t, J=7.5 Hz, 6H, 2×CH₃), 1.36 (t, J=7.1 Hz, 3H, CH₃), 2.03 (m, J=4.4 Hz, 2H, CH₂), 2.53 (m, J=7.5 Hz, 4H, 2×CH₂), 2.67 (t, J=6.5 Hz, 2H, CH₂), 4.15 (t, J=5.2 Hz, 2H, CH₂), 4.38 (q, J=7.1 Hz, 2H, OCH₂), 6.61 (s, 1H, CH). ¹³C NMR $(CDCl_3, 75 \text{ MHz}): \delta_C = 14.1, 14.2, 15.6 (CH_3), 21.6, 22.0,$ 25.4, 26.3, 60.8, 66.0 (CH₂), 117.8 (C), 119.8 (CH), 120.5, 139.5, 144.4, 151.6, 168.7 (C). IR (neat, cm^{-1}): $\tilde{\nu} = 2969$ (s), 2937 (s), 2874 (s), 1728 (s), 1609 (s), 1571 (s), 1463 (s), 1442 (s), 1417 (s), 1370 (m), 1276 (s), 1248 (s), 1150 (s), 1113 (s), 1066 (s), 868 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=207 (4.53), 284 (3.38) nm. MS (EI, 70 eV): m/z (%)=263 ([M+1]⁺, 6), 262 (M⁺, 50), 217 (73), 216 (100), 215 (34), 189 (15), 188 (15), 187 (17), 159 (9), 91 (13), 28 (36). Anal. Calcd for C₁₆H₂₂O₃ (262.344): C, 73.53; H, 8.10. Found: C, 73.49; H, 8.94.

4.5.6. Ethyl 3,4-dihydro-3,5,6,7-tetramethyl-2H-chromene-8-carboxylate (4f). Starting with 3f (0.230 g, 0.77 mmol), NaH (0.028 g, 1.15 mmol), and TBAI (0.503 g, 1.54 mmol) in THF (12 mL), 4f was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.190 g, 94%), mp=111 °C. ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.05$ (d, J = 6.5 Hz, 3H, CH₃), 1.34 (t, J=7.1 Hz, 3H, CH₃), 2.09 (m, 1H, CH), 2.13 (s, 6H, 2×CH₃), 2.17 (s, 3H, CH₃), 2.22 (m, 1H, CH₂), 2.74 (dq, J=10.1, 1.8 Hz, 1H, CH₂), 3.57 (m, J=10 Hz, 1H, CH₂), 4.12 (m, J=5.3, 1.8 Hz, 1H, CH₂), 4.39 (q, J=7.1 Hz, 2H, OCH₂). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =14.3, 15.3, 15.5, 17.1, 17.3 (CH₃), 27.3 (CH), 31.9, 60.9, 71.2 (CH₂), 118.4, 121.4, 126.9, 130.9, 136.6, 148.8, 169.4 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 2983$ (m), 1726 (s), 1464 (m), 1268 (s), 1185 (s), 1123 (m), 1042 (s). UV-vis (CH₃CN, nm): λ_{max} $(\log \varepsilon) = 203$ (4.57), 288 (3.43) nm. MS (EI, 70 eV): m/z $(\%)=263 ([M+1]^+, 16), 262 (M^+, 100), 217 (89), 216 (40),$ 188 (39), 175 (21), 146 (11), 91 (12), 32 (17), 28 (80). Anal. Calcd for C₁₆H₂₂O₃ (262.344): C, 73.25; H, 8.45. Found: C, 72.85; H, 7.98.

4.5.7. Ethyl 3,4-dihydro-3,5,7-trimethyl-2H-chromene-8carboxylate (4g). Starting with 3g (0.176 g, 0.62 mmol), NaH (0.039 g, 1.63 mmol), and TBAI (0.771 g, 2.18 mmol) in THF (12 mL), 4g was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.123 g, 80%), mp=71 °C. ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.05$ (d, J = 6.3 Hz, 3H, CH₃), 1.36 (t, J = 7.1 Hz, 3H, CH₃), 2.10 (m, 1H, CH), 2.16 (s, 3H, CH₃), 2.22 (s, 3H, CH₃), 2.18 (m, 1H, CH₂), 2.68 (m, 1H, CH₂), 3.61 (m, J=12 Hz, 1H, CH₂), 4.15 (m, J=5.5 Hz, 1H, CH₂), 4.38 (q, J=7.1 Hz, 2H, OCH₂), 6.57 (s, 1H, CH of Ar). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.3, 17.2, 18.9, 19.0 (CH₃), 26.9 (CH), 30.9, 60.9, 71.5 (CH₂), 110.9, 118.4, 120.7 (C), 123.2 (CH), 133.2, 138.5, 151.4, 168.7 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 3442$ (m), 2978 (s), 1728 (s), 1612 (m), 1574 (m), 1452 (m), 1282 (s), 1265 (s), 1151 (s), 1056 (s), 1042 (s), 862 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=206 (4.52), 284 (3.39) nm. MS (EI, 70 eV): m/z (%)=249 ([M+1]⁺, 8), 248 (M⁺, 100), 202 (66), 161 (21), 32 (22), 28 (100). Anal. Calcd for C₁₅H₂₀O₃ (248.318): C, 72.55; H, 8.12. Found: C, 72.10; H, 8.43.

4.5.8. Ethyl 5,7-diethyl-3,4-dihydro-3-methyl-2H-chromene-8-carboxylate (4h). Starting with 3h (0.450 g, 1.44 mmol), NaH (0.052 g, 2.16 mmol), and TBAI (0.941 g, 2.88 mmol) in THF (24 mL), 4h was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.385 g, 97%), mp=42 °C. ¹H NMR (CDCl₃, 300 MHz): δ =1.05 (d, J=6.5 Hz, 3H, CH₃), 1.20 $(q, J=7.0 \text{ Hz}, 6\text{H}, 2\times \text{CH}_3), 1.36 (t, J=7.1 \text{ Hz}, 3\text{H}, \text{CH}_3),$ 2.14 (m, 1H, CH₂), 2.24 (m, 1H, CH₂), 2.53 (m, 4H, 2×CH₂), 2.75–2.79 (m, 1H, CH), 3.62 (dd, J=10 Hz, 1H, OCH₂), 4.15–4.19 (dd, J=2.4 Hz, 1H, OCH₂), 4.38 (q, J=7.1 Hz, 2H, OCH₂), 6.61 (s, 1H, CH of Ar). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =14.6, 14.7, 16.1, 17.7 (CH₃), 25.9, 26.7 (CH₂), 27.3 (CH), 30.7, 61.3, 71.9 (CH₂), 117.7, 119.9 (C), 120.4 (CH), 139.6, 144.4, 151.2, 168.8 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 2967$ (s), 2933 (s), 2875 (s), 1728 (s), 1610 (m), 1571 (s), 1462 (s), 1417 (s), 1274 (s), 1242 (s), 1150 (s), 1261 (s), 1044 (s), 866 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=208 (4.53), 284 (3.39) nm. MS (EI, 70 eV): m/z (%)=277.6 ([M+1]⁺, 21), 276.7 (M⁺, 100), 231 (39), 230 (64), 229 (16), 189 (8), 188 (7), 29 (6). HRMS (ESI): calcd for C₁₇H₂₄O₃ ([M+1]⁺): 277.18037, found: 277.18035.

4.5.9. Ethyl 3,4,6,7,8,9-hexahydro-2H-benzo[g]chromene-10-carboxylate (4i). Starting with 3i (311 mg, 1.05 mmol), NaH (38 mg, 1.58 mmol), and TBAI (685 mg, 2.10 mmol) in THF (20 mL), 4i was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless oil (0.189 g, 70%). ¹H NMR (CDCl₃, 300 MHz): δ=1.36 (t, J=7.2 Hz, 3H, CH₃), 1.71–1.76 (m, J=3.3 Hz, 4H, 2×CH₂), 1.97 (m, J=4.3 Hz, 2H, CH₂), 2.65 (m, 6H, 3×CH₂), 2.71 (t, J=6.5 Hz, 2H, CH₂), 4.16 (t, J=5.2 Hz, 2H, CH₂), 4.36 (q, J=7.1 Hz, 2H, OCH₂), 6.77 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =14.3 (CH₃), 22.2, 22.8, 22.9, 24.5, 26.2, 28.8, 60.9, 66.6 (CH₂), 111.9, 122.4, 128.7, 131.1, 132.3, 149.4, 168.7 (C). IR (neat, cm^{-1}): $\tilde{\nu} = 2977$ (s), 2931 (s), 2858 (s), 1729 (s), 1582 (s), 1476 (s), 1446 (s), 1367 (s), 1285 (s), 1249 (s), 1179 (s), 1164 (s), 1108 (s), 1061 (s), 961 (s), 866 (s), 724 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=204 (4.41), 294 (3.55) nm. MS (EI, 70 eV): m/z (%)=261 ([M+1]⁺, 6), 260 (M⁺, 50), 214 (64), 186 (23), 168 (12), 153 (16), 128 (6), 114 (6), 91 (9), 28 (100). HRMS (ESI): calcd for $C_{16}H_{20}O_3$ ([M+1]⁺): 261.14907; found: 261.14928. Anal. Calcd for C₁₆H₂₀O₃ (260.328): C, 73.81; H, 7.74. Found: C, 73.51; H, 8.02.

4.5.10. Ethyl 3,4,6,7,8,9-hexahydro-5-methyl-2Hbenzo[g]chromene-10-carboxylate (4j). Starting with 3j (0.305 g, 0.98 mmol), NaH (0.035 g, 1.47 mmol), and TBAI (0.640 g, 1.96 mmol) in THF (18 mL), 4j was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.234 g, 87%), mp=74 °C. ¹H NMR (300 MHz, CDCl₃): δ=1.38 (t, J=7.2 Hz, 3H, CH₃), 1.69-1.79 (m, 4H, 2×CH₂), 2.00–2.06 (m, 2H, CH₂), 2.10 (s, 3H, CH₃), 2.58 (t, J=6.5 Hz, 2H, CH₂), 2.64 (m, 4H, 2 CH₂), 4.13 (t, J=5.2 Hz, 2H, CH₂), 4.36 (q, J=7.1 Hz, 2H, OCH₂). ¹³C NMR (CDCl₃, 75 MHz): δ_{C} =14.2, 14.3 (CH₃), 22.4 (2 CH₂), 22.9, 23.1, 23.2, 26.9, 60.8, 65.8 (CH₂), 118.7, 120.6, 127.1, 131.9, 136.9, 149.3, 168.9 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 3430$ (w), 2931 (s), 1725 (s), 1579 (m), 1445 (m), 1272 (s), 1188 (s), 1076 (m), 1034 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=206 (4.51), 290 (4.47) nm. MS (EI, 70 eV): m/z (%)=275 ([M+1]⁺, 3), 274 $(M^+, 20), 229 (17), 228 (21), 174 (29), 114 (4), 91 (4), 32$ (25), 28 (100). Anal. Calcd for C₁₇H₂₂O₃ (274.355): C, 74.42; H, 8.09. Found: C, 74.31; H, 8.18.

4.5.11. Ethyl 6,8,9,10-tetrahydro-7-methyl-5*H***-naphtho[2,1-g]chromene-12-carboxylate (4k). Starting with 3k (0.353 g, 0.984 mmol), NaH (0.035 g, 1.48 mmol), and TBAI (0.643 g, 1.97 mmol) in THF (18 mL), 4k was isolated after chromatography (silica gel,** *n***-hexane/EtOAc = 20:1) as a colorless solid (0.280 g, 88%), mp=180 °C. ¹H NMR (CDCl₃, 300 MHz): \delta=1.18 (t,** *J***=7.1 Hz, 3H, CH₃), 2.09 (m,** *J***=4.0 Hz, 2H, CH₂), 2.21 (s, 3H, CH₃), 2.69– 2.77 (m, 6H, 3×CH₂), 4.18 (t,** *J***=5.2 Hz, 2H, CH₂), 4.29 (q,** *J***=7.1 Hz, 2H, OCH₂), 7.17–7.23 (m, 3H, 3×CH of Ar), 7.54–7.57 (m, 1H, CH of Ar). ¹³C NMR (CDCl₃, 75 MHz): \delta_{C}=13.7, 15.1 (CH₃), 22.3, 23.4, 25.4, 29.4, 61.2, 65.9 (CH₂), 118.4, 120.7 (C), 126.2, 126.3, 127.2, 127.3 (CH), 129.5, 131.2, 133.9, 135.7, 138.6, 151.0,** 169.7 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 3414$ (w), 2986 (m), 1717 (s), 1558 (m), 1415 (m), 1282 (s), 1188 (m), 1164 (m), 1070 (m), 1033 (m), 757 (m). UV–vis (CH₃CN, nm): λ_{max} (log ε)=208 (4.49), 225 (4.38), 269 (4.12), 316 (3.87) nm. MS (EI, 70 eV): m/z (%)=323 ([M+1]⁺, 22), 322 (M⁺, 100), 277 (54), 32 (24), 28 (92). HRMS (ESI): calcd for C₂₁H₂₂O₃ ([M+1]⁺): 323.16472; found: 323.16431. Anal. Calcd for C₂₁H₂₂O₃ (322.398): C, 78.23; H, 6.88. Found: C, 77.99; H, 7.29.

4.5.12. Ethyl 6-(2-chloroethyl)-5.7-dimethyl-3.4-dihydro-2H-chromene-8-carboxylate (41). Starting with 31 (0.308 g. 0.923 mmol), NaH (0.033 g, 1.36 mmol), and TBAI (0.603 g, 1.85 mmol) in THF (16 mL), 4l was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.211 g, 77%), mp=103 °C. ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.37$ (t, J = 7.2 Hz, 3H, CH₃), 2.02 (m, J=7.5 Hz, 2H, CH₂), 2.18 (s, 3H, CH₃), 2.25 (s, 3H, CH₃), 2.63 (t, J=6.6 Hz, 2H, CH₂), 3.10 (m, 2H, CH₂), 3.47 (m, 2H, CH2-Cl), 4.12 (t, J=5.2 Hz, 2H, CH2), 4.37 (q, J=7.1 Hz, 2H, OCH₂). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.2, 15.2, 16.5 (CH₃), 22.3, 23.2, 33.2, 42.3, 61.1, 65.9 (CH₂), 119.4, 122.4, 126.5, 131.4, 137.3, 150.4, 168.9 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 2987$ (m), 2939 (m), 1727 (s), 1579 (m), 1453 (s), 1308 (s), 1278 (s), 1244 (s), 1186 (s), 1115 (s), 1042 (s), 722 (w). UV-vis (CH₃CN, nm): λ_{max} $(\log \varepsilon) = 208$ (4.58), 288 (4.35) nm. MS (EI, 70 eV): m/z $(\%)=298 \text{ (M}^{+}[^{37}\text{Cl}], 10), 296 \text{ (M}^{+}[^{35}\text{Cl}], 34), 247 (100),$ 201 (17), 173 (3), 114 (4), 28 (7). HRMS (ESI): calcd for $C_{16}H_{21}ClO_3$ ([M+1]⁺): 299.12280 [³⁷Cl], 297.12575 [³⁵Cl]; found: 299.12162 [³⁷Cl], 297.12476 [³⁵Cl]. Anal. Calcd for C₁₆H₂₁ClO₃ (296.789): C, 64.73; H, 7.13. Found: C, 64.73; H, 7.72.

4.5.13. Ethyl 6-(2-bromoethyl)-3,4-dihydro-5,7-dimethyl-2H-chromene-8-carboxylate (4m). Starting with 3m (0.129 g, 0.34 mmol), NaH (0.012 g, 0.51 mmol), and TBAI (0.222 g, 0.68 mmol) in THF (6 mL), 4m was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a colorless solid (0.070 g, 60%). ¹H NMR (CDCl₃, 300 MHz): $\delta = 1.36$ (t, J=7.1 Hz, 3H, CH₃), 2.02 (quint, J=5.3 Hz, 2H, CH₂), 2.17 (s, 3H, CH₃), 2.22 (s, 3H, CH₃), 2.63 (t, J=6.6 Hz, 2H, CH₂), 3.06–3.19 (m, 2H, CH₂), 3.44-3.49 (m, 2H, CH₂), 4.12 (t, J=5.3 Hz, 2H, CH₂), 4.36 (q, J=7.2 Hz, 2H, OCH₂). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}$ =14.3, 15.2, 16.4 (CH₃), 22.3, 23.2, 33.2, 33.6, 61.1, 65.9 (CH₂), 119.5, 126.5, 131.3, 137.3, 150.4, 219.7 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 3431$ (m), 2981 (m), 2961 (m), 2937 (m), 1726 (s), 1581 (m), 1451 (s), 1305 (s), 1277 (s), 1186 (s), 1115 (s), 1041 (s), 962 (m), 793 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=210 (4.52), 289 (3.38) nm. MS (EI, 70 eV): m/z (%)=342 (M⁺[⁸¹Br], 6), 340 (M⁺[⁷⁹Br], 5), 296 (23), 260 (33), 247 (100), 215 (30), 153 (9), 114 (10), 84 (88), 41 (29), 28 (78). HRMS (ESI): calcd for C₁₆H₂₁BrO₃ ([M+1]⁺): 343.07317 [⁸¹Br], 341.07522 ^{[79}Br]; found: 343.07428 [⁸¹Br], 341.07612 [⁷⁹Br].

4.5.14. Ethyl 3,4-dihydro-6-(2-hydroxybenzoyl)-2*H***-chromene-8-carboxylate (11a).** A THF solution (5 mL) of **10a** (149 mg, 0.41 mmol) was added to a mixture of NaH (14.8 mg, 0.61 mmol) and TBAI (304 mg, 0.82 mmol). After stirring for 20 h at 20 °C, an aqueous solution of NH₃Cl (1 M, 4 mL) was added. The organic layer was

separated and the aqueous layer was extracted with Et₂O $(5 \times 10 \text{ mL})$. The layers were separated and the organic layer was washed with water, dried (Na₂SO₄), filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, *n*-hexane/EtOAc = $3:1 \rightarrow 1:1$) to give **11a** as a yellow solid (92 mg, 68%), mp=119 °C. ^IH NMR (300 MHz, CDCl₃) δ =1.36 (t, J=7.1 Hz, 3H, OCH₂CH₃), 2.10 (m, 2H, CH₂CH₂CH₂), 2.90 (t, J=6.3 Hz, 2H, ArCH₂), 4.32–4.42 (m, 4H, CH₂Cl, OCH_2CH_3), 6.91 (m, 1H, Ar), 7.07 (dd, J=8.1 Hz, J=1.0 Hz, 1H, Ar), 7.51 (m, 1H, Ar), 7.61 (m, 2H, Ar), 7.99 (d, J=2.3 Hz, 1H, Ar), 11.89 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): δ=14.25 (OCH₂CH₃), 21.33 (CH₂CH₂CH₂), 25.23 (ArCH₂), 61.10 (OCH₂CH₃), 67.64 (OCH₂), 118.41, 118.67 (CH), 119.16, 119.58, 123.76, 128.80 (C), 131.45, 133.08, 134.73, 136.04 (CH), 158.15, 162.96 (C), 165.30, 199.40 (C=O). IR (KBr): $\tilde{\nu} = 3070 \text{ (w)}, 3035 \text{ (w)}, 2941 \text{ (w)}, 1692 \text{ (s)}, 1626 \text{ (s)},$ 1622 (s), 1480 (s), 1456 (m), 1335 (m), 1276 (s), 1250 (s), 1216 (s), 1184 (s), 1159 (s), 1135 (m), 1021 (m), 762 (w) cm⁻¹. UV–vis (CH₃CN): λ_{max} (log ε): 302 (3.99), 248 (4.07), 214 (4.29) nm. Fluorescence (CH₃CN): λ_{Ex} (F λ_{max}): 340 (379) nm. MS (EI, 70 eV): *m/z* (%)=326 (M⁺, 36), 270 (68), 234 (14), 210 (100), 182 (18), 161 (12), 128 (32), 77 (16). HRMS (FT-ICR): calcd for $C_{19}H_{19}O_5$ ([M+1]⁺): 327.12270; found: 327.12296.

4.6. General procedure for the synthesis of (11b,e-h)

A THF solution of **10b,e–h** (1.0 equiv) was added to a mixture of NaH (1.5 equiv) and TBAI (2 equiv). After stirring for 20 h at 20 °C, an aqueous solution of hydrochloric acid (10%) was added. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (5×10 mL). The layers were separated and the organic layer was washed with water, dried (Na₂SO₄), filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, *n*-hexane/EtOAc = 20:1 \rightarrow 10:1) to give **11b,e–h**.

4.6.1. 3,4-Dihydro-6-(2-hydroxy-5-methylbenzoyl)-2Hchromene-8-carboxylic acid (11b). Starting with 10b (102 mg, 0.27 mmol) in 4 mL THF, NaH (10 mg, 0.405 mmol), and TBAI (176 mg, 0.54 mmol), 11b was isolated as a yellow solid (80 mg, 94%). ¹H NMR (300 MHz, CDCl₃): δ =2.18 (quint, J=5.2 Hz, 2H, CH₂), 2.26 (s, 3H, CH₃), 2.97 (t, J=6.1 Hz, 2H, CH₂), 4.55 (t, J=5.4 Hz, 2H, CH₂), 6.96 (d, J=7.8 Hz, 1H, Ar), 7.32–7.35 (m, 2H, Ar), 7.69 (d, J=2.2 Hz, 1H, Ar), 8.30 (d, J=2.2 Hz, 1H, Ar), 11.62 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): $\delta = 20.5$ (CH₃), 21.2, 24.6, 68.9 (CH₂), 116.7 (C), 118.2 (CH), 118.6, 124.1, 128.1, 130.9 (C), 132.7, 133.2, 135.8, 137.5 (CH), 156.5, 160.9, 164.8, 199.2 (C). IR (KBr): $\tilde{\nu} = 3225$ (m), 1731 (s), 1630 (m), 1594 (s), 1478 (s), 1427 (s), 1336 (s), 1249 (s), 1205 (s), 788 (m) cm⁻¹. MS (EI, 70 eV): *m/z* (%)=312 (M⁺, 42), 264 (25), 57 (12), 44 (42), 28 (100). Anal. Calcd for C₁₈H₁₆O₅: C, 69.22; H, 5.16. Found: C, 69.64; H, 5.38.

4.6.2. 3,4-Dihydro-6-(5-chloro-2-hydroxy-4-methylbenzoyl)-2*H***-chromene-8-carboxylic acid (11e). Starting with 10e** (102 mg, 0.25 mmol) in 4 mL THF, NaH (9 mg, 375 mmol), and TBAI (163 mg, 0.5 mmol), **11e** was isolated as yellow viscous oil (60 mg, 70%). ¹H NMR (300 MHz, CDCl₃): δ =2.19 (quint, *J*=5.0 Hz, 2H, CH₂), 2.40 (s, 3H, CH₃), 2.98 (t, *J*=6.2 Hz, 2H, CH₂), 4.56 (t, *J*=5.2 Hz, 2H, CH₂), 6.97 (s, 1H, Ar), 7.49 (s, 1H, Ar), 7.65 (t, *J*=1 Hz, 1H, Ar), 8.31 (d, *J*=2.3 Hz, 1H, Ar), 11.68 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): δ =20.8 (CH₃), 21.2, 24.6, 68.9 (CH₂), 117.1, 117.9 (C), 120.5 (CH), 124.2, 130.5 (C), 132.3, 133.0, 135.6 (CH), 145.9, 156.7, 161.4, 164.5, 190.5, 197.9 (C). MS (EI, 70 eV): *m/z* (%)=348 (M⁺[³⁷Cl], 21), 346 (M⁺[³⁵Cl], 59), 205 (17), 178 (79), 168 (43), 161 (100), 77 (53).

4.6.3. 3,4-Dihydro-3-methyl-6-(2-hydroxybenzoyl)-2Hchromene-8-carboxylic acid (11f). Starting with 10f (94 mg, 0.25 mmol) in 10 mL THF, NaH (9 mg, 0.37 mmol), and TBAI (163 mg, 0.50 mmol), 11f was isolated as a yellow viscous oil (55 mg, 71%). ¹H NMR (300 MHz, CDCl₃): δ=1.22 (d, J=6.5 Hz, 3H, CH₃(CH)), 2.34 (m, 1H, CH₃(CH)), 2.62 (q, J=9.8, 6.5 Hz, 1H, CH₂), 3.00 (dd, J=5.0, 9.5 Hz, 1H, CH₂), 4.04 (t, J=10.5 Hz, 1H, CH₂), 4.54–4.59 (qq, J=2.0, 9.0 Hz, 1H, CH₂), 6.99 (d, J=8.1 Hz, 1H, Ar), 7.32 (s, 1H, Ar), 7.35 (d, J=2.2 Hz, 1H, Ar), 7.68 (t, *J*=1.1 Hz, 1H, Ar), 8.32 (d, *J*=2.2 Hz, 1H, Ar), 11.63 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): $\delta = 16.5$ (CH₃), 26.3 (CH), 32.7, 73.8 (CH₂), 116.6 (C), 118.5 (CH), 118.8 (C), 119.0 (CH), 123.8, 130.9 (C), 133.0, 133.3, 135.9, 136.4 (CH), 156.1, 163.0, 164.6, 199.1 (C). MS (EI, 70 eV): m/z (%)=312 (M⁺, 64), 267 (20), 219 (26), 192 (100), 175 (39), 121 (60). IR (KBr): $\tilde{\nu} = 3296$ (br, m), 2926 (m), 1733 (m), 1625 (s), 1598 (s), 1479 (s), 1329 (s), 1249 (s), 1158 (s), 762 (m) cm⁻¹ HRMS (ESI): calcd for C₁₈H₁₆O₅: 312.09977; found: 312.09901.

4.6.4. 3,4-Dihydro-3-methyl-6-(2-hydroxy-5-methylbenzoyl)-2H-chromene-8-carboxylic acid (11g). Starting with 10g (194 mg, 0.50 mmol) in 10 mL THF, NaH (18 mg, 0.75 mmol), and TBAI (326 mg, 1.0 mmol), 11g was isolated as a yellow solid (140 mg, 86%). ¹H NMR (300 MHz, CDCl₃): δ =1.15 (d, J=6.8 Hz, 3H, CH₃(CH)), 2.26 (s, 3H, CH₃), 2.34 (m, 1H, CH₃(CH)), 2.62 (q, J=9.8, 6.5 Hz, 1H, CH₂), 3.00 (dd, J=5.0, 9.5 Hz, 1H, CH₂), 4.04 (t, J=10.5 Hz, 1H, CH₂), 4.54–4.59 (qq, J=2.0, 9.0 Hz, 1H, CH₂), 6.99 (d, J=8.1 Hz, 1H, Ar), 7.32 (s, 1H, Ar), 7.35 (d, J=2.2 Hz, 1H, Ar), 7.68 (t, J=1.1 Hz, 1H, Ar), 8.32 (d, J=2.2 Hz, 1H, Ar), 11.63 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): δ =16.5, 20.5 (CH₃), 26.3 (CH), 32.8, 73.8 (CH₂), 116.5 (C), 118.2 (CH), 118.6, 123.8, 128.1, 131.2 (C), 132.7, 133.2, 135.8, 137.5 (CH), 156.0, 160.9, 164.7, 199.2 (C). IR (KBr): $\tilde{\nu} = 2956$ (m), 2926 (m), 1670 (s), 1596 (s), 1479 (s), 1336 (s), 1246 (s), 1219 (s), 1173 (s), 792 (m) cm⁻¹. MS (EI, 70 eV): m/z $(\%)=326 (M^+, 90), 175 (100), 134 (91), 77 (15), 28 (29).$ HRMS (ESI): calcd for C₁₉H₁₈O₅: 326.11542; found: 326.11530. Anal. Calcd for C₁₉H₁₈O₅: C, 69.93; H, 5.56. Found: C, 69.51; H, 5.56.

4.6.5. 3,4-Dihydro-3-methyl-6-(5-chloro-2-hydroxybenzoyl)-2*H***-chromene-8-carboxylic acid (11h). Starting with 10h** (261 mg, 0.64 mmol) in 10 mL THF, NaH (23 mg, 0.96 mmol), and TBAI (662 mg, 1.27 mmol), **11h** was isolated as a yellow solid (160 mg, 73%). ¹H NMR (300 MHz, CDCl₃): δ =1.16 (d, *J*=6.8 Hz, 3H, CH₃(CH)), 2.34 (m, 1H, CH₃(CH)), 2.62 (q, J=9.8, 6.6 Hz, 1H, CH₂), 2.99–3.06 (dd, J=3.2, 13.3 Hz, 1H, CH_2), 4.04 (t, J=10.1 Hz, 1H, CH₂), 4.55–4.60 (qq, J=2.0, 8.6 Hz, 1H, CH₂), 7.04 (td, J=1.2, 6.9 Hz, 1H, Ar), 7.06–7.09 (dd, J=2.0, 7.6 Hz, 1H, Ar), 7.49–7.58 (m, 2H, Ar), 7.70 (quint, J=1.0 Hz, 1H, Ar), 8.34 (d, J=2.3 Hz, 1H, Ar), 11.82 (s, 1H, OH). ¹³C NMR (DEPT, 75.5 MHz, CDCl₃): δ =16.5 (CH₃), 26.2 (CH), 32.8, 73.8 (CH₂), 116.9, 119.6 (C), 120.1 (CH), 123.6, 123.9, 130.3 (C), 131.8, 133.1, 135.7, 136.3 (CH), 156.5, 161.5, 164.6, 198.2 (C). IR (KBr): $\tilde{\nu} = 3069$ (w), 2959 (m), 1735 (m), 1706 (m), 1674 (s), 1627 (s), 1596 (s), 1474 (s), 1466 (s), 1330 (s), 1249 (s), 1226 (s), 1185 (s), 1140 (m), 1001 (m), 790 (m) cm⁻¹. UV-vis (CH₃CN): λ_{max} (log ε)=209.1 (4.49), 291.6 (3.93), 344.8 (3.77) nm. MS (EI, 70 eV): m/z (%)=348 (M⁺[³⁷Cl], 22), 346 (M⁺[³⁵Cl], 62), 192 (100), 175 (66), 155 (24). Anal. Calcd for C₁₈H₁₅O₅Cl: C, 62.35; H, 4.36. Found: C, 62.11; H, 4.34.

4.6.6. 5-Bromo-2,3-dihydro-6-hydroxy-1H-naphtho-[2,3-f]chromene-7,12-dione (14). Starting with 13 (0.140 g, 0.44 mmol), NaH (0.016 g, 0.66 mmol), and TBAI (0.287 g, 0.88 mmol) in THF (7 mL), 14 was isolated after chromatography (silica gel, *n*-hexane/EtOAc = 20:1) as a yellowish solid (0.115 g, 73%), mp=235 °C. ¹H NMR (CDCl₃, 300 MHz): δ =2.10 (tt, J=5.5, 6.5 Hz, 2H, CH₂), 3.36 (t, J=6.7 Hz, 2H, CH₂), 4.44 (t, J=6.2 Hz, 2H, CH₂), 7.77-7.79 (m, 2H, 2×CH of Ar), 8.20-8.28 (m, 2H, 2×CH of Ar), 14.23 (s, 1H, OH). ¹³C NMR (CDCl₃, 75 MHz): $\delta_{\rm C}=21.9, 25.0, 67.9 ({\rm CH}_2), 106.5, 111.4, 121.2 ({\rm C}),$ 126.4, 127.2 (CH), 129.9, 132.2 (C), 133.8, 134.3, 134.4 (CH), 159.4, 160.2, 184.3, 187.4 (C). IR (KBr, cm⁻¹): $\tilde{\nu} = 2921$ (w), 1661 (m), 1631 (s), 1586 (s), 1556 (m), 1439 (m), 1396 (s), 1355 (s), 1282 (s), 1152 (s), 959 (m), 797 (m), 729 (m). UV-vis (CH₃CN, nm): λ_{max} (log ε)=206 (4.46), 250 (4.42), 277 (4.43), 332 (3.43), 414 (3.89) nm. MS (EI, 70 eV): m/z (%)=360 (M⁺[⁸¹Br], 16), 359 (96), 358 (M⁺[⁷⁹Br], 21), 357 (100), 342.7 (28), 164.9 (11), 139.0 (12), 77.4 (8), 32.0 (20), 28 (89). Anal. Calcd for C₁₇H₁₁BrO₄ (359.171): C, 56.83; H, 3.09. Found: C, 56.43; H, 3.64.

Acknowledgements

We thank Dr. Dirk Michalik for NMR studies. Financial support by the state of Vietnam (MOET scholarship for V.T.H.N.), by the Deutsche Forschungsgemeinschaft, and by the state of Mecklenburg-Vorpommern (Landesforschungsschwerpunkt 'Neue Wirkstoffe und Screeningverfahren') is gratefully acknowledged.

References and notes

- (a) Comprehensive Heterocyclic Chemistry II; Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Elsevier Science: Oxford, 1996; (b) Comprehensive Heterocyclic Chemistry; Katritzky, A. R., Rees, C. W., Eds.; Elsevier Science: Oxford, 1984.
- (a) Bavachromanol: ElSohly, H. N.; Joshi, A. S.; Nimrod, A. C.; Walker, L. A.; Clark, A. M. *Planta Med.* 2001, 67, 87;
 (b) Calyxin L: Tezuka, Y.; Gewali, M. B.; Ali, M. S.; Banskota, A. H.; Kadota, S. *J. Nat. Prod.* 2001, 64, 208; (c) Vismiaguianone E: Seo, E.-K.; Wani, M. C.; Wall, M. E.;

Navarro, H.; Mukherjee, R.; Farnsworth, N. R.; Kinghorn, A. D. Phytochemistry 2000, 55, 35; (d) Ali, S.; Goundar, R.; Sotheeswaran, S.; Beaulieu, C.; Spino, C. Phytochemistry 2000, 53, 281; (e) Grandinal: Singh, I. P.; Hayakawa, R.; Etoh, H.; Takasaki, M.; Konoshima, T. Biosci. Biotechnol. Biochem. 1997, 61, 921; (f) Hericenone F: Kawagishi, H.; Ando, M.; Shinba, K.; Sakamoto, H.; Yoshida, S. Phytochemistry 1993, 32, 175; (g) Calomelanol A: Asai, F.; Iinuma, M.; Tanaka, T.; Mizuno, M. Phytochemistry 1991, 30, 3091; (h) Flemistrictin F: Subrahmanyam, K.; Rao, J. M.; Vemuri, V. S. S.; Babu, S. S.; Roy, C. P.; Rao, K. V. J. Indian J. Chem., Sect. B 1982, 21, 895; (i) Iryantherin E: Conserva, L. M.; Yoshida, M.; Gottlieb, O. R.; Martinez, V. J. C.; Gottlieb, H. E. Phytochemistry 1990, 29, 3911; (j) Bohlmann, F.; Vorwerk, E. Chem. Ber. 1981, 114, 147.

- 3. Wang, Q.; Finn, M. G. Org. Lett. 2000, 2, 4063.
- 4. Jones, R. M.; Selenski, C.; Pettus, T. R. R. J. Org. Chem. 2002, 67, 6915.
- 5. For a review of 1,3-bis-silyl enol ethers, see: Langer, P. *Synthesis* **2002**, 441.
- (a) Chan, T.-H.; Brownbridge, P. J. Chem. Soc., Chem. Commun. 1979, 578; (b) Molander, G. A.; Cameron, K. O. J. Am. Chem. Soc. 1993, 115, 830.
- 7. Nguyen, V. T. H.; Langer, P. Tetrahedron Lett. 2005, 46, 815.
- For chloro-substituted mono-silyl enol ethers, see: (a) Fleming,
 F. F.; Shook, B. C.; Jiang, T.; Steward, O. W. *Tetrahedron* 2003,
 59, 737; (b) Hydrio, J.; van de Weghe, P.; Collin, J. *Synthesis*

1997, 68; (c) Limat, D.; Schlosser, M. Tetrahedron 1995, 51, 5799; (d) Masters, A. P.; Parvez, M.; Sorensen, T. S.; Sun, F. J. Am. Chem. Soc. 1994, 116, 2804; (e) Stack, D. E.; Dawson, B. T.; Rieke, R. D. J. Am. Chem. Soc. 1991, 113, 4672; (f) Hambly, G. F.; Chan, T. H. Tetrahedron Lett. 1986, 27, 2563; (g) Chatani, N.: Fuiii, S.: Yamasaki, Y.: Murai, S.: Sonoda, N. J. Am. Chem. Soc. 1986, 108, 7361; (h) Poirier, J.-M.; Hennequin, L. Synth. Commun. 1985, 15, 217; (i) Schultz, A. G.; Dittami, J. P. J. Org. Chem. 1983, 48, 2318; (j) Chatani, N.; Murai, S.; Sonoda, N. J. Am. Chem. Soc. 1983, 105, 1370; For bromo-substituted mono-silyl enol ethers, see: (k) Marko, I. E.; Dumeunier, R.; Leclercq, C.; Leroy, B.; Plancher, J.-M.; Mekhalfia, A.; Bayston, D. J. Synthesis 2002, 958; (1) Oku, A.; Miki, T.; Abe, M.; Ohira, M.; Kamada, T. Bull. Chem. Soc. Jpn. 1999, 72, 511; (m) Rigby, J. H.; Rege, S. D.; Sandanayaka, V. P.; Kirova, M. J. Org. Chem. 1996, 61, 842.

- Nguyen, V. T. H.; Bellur, E.; Appel, B.; Langer, P. Synthesis 2006, 1103.
- (a) Langer, P.; Bose, G. Angew. Chem. 2003, 115, 4165; Angew. Chem., Int. Ed. 2003, 42, 4033; (b) Bose, G.; Nguyen, V. T. H.; Ullah, E.; Lahiri, S.; Görls, H.; Langer, P. J. Org. Chem. 2004, 69, 9128.
- 11. Langer, P.; Appel, B. Tetrahedron Lett. 2003, 44, 7921.
- (a) Roberge, G.; Brassard, P. Synthesis 1981, 381; (b) Roberge,
 G.; Brassard, P. J. Org. Chem. 1981, 46, 4161; (c) Couturier,
 M.; Brassard, P. Synthesis 1994, 703.